<SEC-DOCUMENT>0001493152-25-013743.txt : 20250916
<SEC-HEADER>0001493152-25-013743.hdr.sgml : 20250916
<ACCEPTANCE-DATETIME>20250916170400
ACCESSION NUMBER:		0001493152-25-013743
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20250914
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250916
DATE AS OF CHANGE:		20250916

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Microbot Medical Inc.
		CENTRAL INDEX KEY:			0000883975
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				943078125
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19871
		FILM NUMBER:		251318019

	BUSINESS ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043
		BUSINESS PHONE:		908-938-5561

	MAIL ADDRESS:	
		STREET 1:		25 RECREATION PARK DR SUITE 108
		CITY:			HINGHAM
		STATE:			MA
		ZIP:			02043

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STEMCELLS INC
		DATE OF NAME CHANGE:	20000524

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CYTOTHERAPEUTICS INC/DE
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:MBOT="http://microbotmedical.com/20250914">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03A_MBOT_microbotmedical.com_20250914 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20250914_20250914 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0000883975 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000004" name="dei:EntityCentralIndexKey">0000883975</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="mbot-20250914.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000883975</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-14</xbrli:startDate>
        <xbrli:endDate>2025-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_90C_edei--DocumentType_c20250914__20250914_zX4JsZIVCer3"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
the Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date
of Report (Date of earliest event reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20250914__20250914_zJJtVbSoyKOg"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 14, 2025</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span id="xdx_90F_edei--EntityRegistrantName_c20250914__20250914_zFrPmYW6hsPg"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000011" name="dei:EntityRegistrantName">MICROBOT
MEDICAL INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_905_edei--EntityIncorporationStateCountryCode_c20250914__20250914_zRSvPXX6yhZb"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityFileNumber_c20250914__20250914_zzyedLVotRu5"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000013" name="dei:EntityFileNumber">000-19871</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_902_edei--EntityTaxIdentificationNumber_c20250914__20250914_z988BBhogg1b"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000014" name="dei:EntityTaxIdentificationNumber">94-3078125</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(State
                                            or other jurisdiction</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>of
    incorporation)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Commission</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>File
    Number)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(IRS
                                            Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Identification
    No.)</b></span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90F_edei--EntityAddressAddressLine1_c20250914__20250914_zc1hFnG3Ax47"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000015" name="dei:EntityAddressAddressLine1">175
Derby St.</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20250914__20250914_zHkLenBDO3al"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000016" name="dei:EntityAddressAddressLine2">Bld. 27</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20250914__20250914_z8nurvPl0b1a"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000017" name="dei:EntityAddressCityOrTown">Hingham</ix:nonNumeric></span>,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20250914__20250914_zZEeV4ZR7BMc"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span> <span id="xdx_90E_edei--EntityAddressPostalZipCode_c20250914__20250914_zzJfs9Rz9ldi"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000019" name="dei:EntityAddressPostalZipCode">02043</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Address
of Principal Executive Offices) (Zip Code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Registrant&#8217;s
telephone number, including area code: <span id="xdx_90E_edei--CityAreaCode_c20250914__20250914_zUa98M40bNM"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000020" name="dei:CityAreaCode">(781)</ix:nonNumeric></span> <span id="xdx_90C_edei--LocalPhoneNumber_c20250914__20250914_zY39HfgxG7Q"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000021" name="dei:LocalPhoneNumber">875-3605</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Former
Name or Former Address, if Changed Since Last Report)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20250914__20250914_zVpQf1NXBfk"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20250914__20250914_zMyK0Ca0eYh2"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--PreCommencementTenderOffer_c20250914__20250914_zJhqU9rfDOGa"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250914__20250914_znylDOP6f4vg"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 38%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--Security12bTitle_c20250914__20250914_ziWY0ZO9aTlg"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000026" name="dei:Security12bTitle">Common
    Stock, $0.01 par value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20250914__20250914_zBaNX0zBYXjl"><ix:nonNumeric contextRef="AsOf2025-09-14" id="Fact000027" name="dei:TradingSymbol">MBOT</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--SecurityExchangeName_c20250914__20250914_zy9Ro8dERiE2"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
    Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_901_edei--EntityEmergingGrowthCompany_c20250914__20250914_zuCiEIXnDg3j"><ix:nonNumeric contextRef="AsOf2025-09-14" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 14, 2025, Microbot Medical Inc., a Delaware corporation (the &#8220;Company&#8221;), entered into an inducement agreement
(the &#8220;Letter Agreement&#8221;) with certain holders (the &#8220;Holders&#8221;) of existing (i) series F preferred investment options
to purchase 207,224 shares of the Company&#8217;s common stock, par value $0.01 per share (the &#8220;Common Stock&#8221;), (ii)
series G preferred investment options to purchase 628,571 shares of Common Stock, (iii) series H preferred investment options
to purchase 4,702,612 shares of Common Stock, and (iv) series I preferred investment options to purchase 8,450,708 shares
of Common Stock (together, the &#8220;Existing PIOs&#8221;). Pursuant to the Letter Agreement, the Holder exercised for cash its
Existing PIOs to purchase an aggregate of 13,989,115 shares of Common Stock, at exercise prices ranging from $1.50 to $2.13 per
share, in consideration for the Company&#8217;s agreement to issue new series J preferred investment options (the &#8220;New PIOs&#8221;)
to purchase up to an aggregate of 13,989,115 shares of Common Stock (the &#8220;New PIO Shares&#8221;) at an exercise price of
$4.50 per share (collectively, the &#8220;Inducement Transaction&#8221;). The New PIOs will be exercisable beginning six months after
issuance and will expire two years thereafter. At the first closing of the Inducement Transaction, which occurred on September
16, 2025, certain Holders exercised Existing PIOs to purchase up to an aggregate of 12,064,627 shares of Common Stock for
cash and received New PIOs to purchase up to an aggregate of 12,064,627 shares of Common Stock (the &#8220;First Closing&#8221;).
At the second closing of the Inducement Transaction, which is expected to occur by no later than October 15, 2025, subject to the satisfaction
of customary closing conditions, a certain Holder will exercise Existing PIOs to purchase up to an aggregate of
1,924,488 shares of Common Stock for cash at an exercise price of $2.10 per share and will receive New PIOs to purchase
up to an aggregate of 1,924,488 shares of Common Stock (the &#8220;Second Closing&#8221;).</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received gross proceeds of approximately $25.2 million from the exercise of certain Existing PIOs by certain Holders
in the First Closing and expects to receive gross proceeds of approximately $4.0 million from the exercise of certain Existing
PIOs by a certain Holder in the Second Closing, in each case prior to deducting offering fees and other expenses
payable by the Company in connection with the Inducement Transaction. The Company expects to use the net proceeds of these transactions
for the continued development, commercialization and regulatory activities for the Company&#8217;s LIBERTY<sup>&#174;</sup> Robotic System,
potential acquisitions of complementary assets or products, expansion and development of additional applications derived from the Company&#8217;s
existing IP portfolio, and for working capital and other general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resale of the shares of the Common Stock issuable upon exercise of the Existing PIOs are registered pursuant to the post-effective
amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113 and 333-284688) and the registration statement on
Form S-3 (File No. 333-285690), declared effective by the SEC on July 3, 2024, April 2, 2025 and April 1, 2025, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Letter Agreement, the Company has agreed to certain restrictions on the issuance and sale of its Common Stock or
Common Stock Equivalents (as defined in the Letter Agreement) during the 90-day period following the date of the First Closing, subject
to certain exceptions. Additionally, the Company agreed not to enter into a variable rate transaction for a period of six months following
the date of the First Closing, subject to certain exceptions. The Company also agreed to file a registration statement on Form S-3 (or
other appropriate form, including on Form S-1, if the Company is not then S-3 eligible) covering the resale of the New PIO Shares
issuable upon the exercise of the New PIOs (the &#8220;Resale Registration Statement&#8221;), within 30 days of the date of the
Letter Agreement, and to use commercially reasonable efforts to have such Resale Registration Statement declared effective by the SEC
within 60 days following the date of the Letter Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 29, 2024, the Company entered into an engagement letter, as amended on January 3, 2025 and on February 9, 2025 (as amended, the &#8220;Engagement
Letter&#8221;), with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;), pursuant to which Wainwright agreed to serve as the exclusive
placement agent for the issuance and sale of securities of the Company, including the Inducement Transaction, pursuant to the Letter
Agreement. As compensation for such placement agent services, the Company has agreed to pay Wainwright an aggregate cash fee equal to
7.0% of the gross proceeds received by the Company from the Offerings, plus a management fee equal to 1.0% of the gross proceeds received
by the Company from the Offerings, a non-accountable expense of $25,000, up to $35,000 for its fees and expenses of legal counsel and
$15,950 for clearing expenses. The Company has also issued to Wainwright or its designees at the First Closing preferred investment
options to purchase an aggregate of (i) 10,362 shares of Common Stock at an exercise price of $1.875 (ii) 31,429 shares of Common Stock
at an exercise price of $2.1875, (iii) 138,906 shares of Common Stock at an exercise price of $2.625 and (iv) 422,535 shares of Common
Stock at an exercise price of $2.6625, and has agreed to issue to Wainwright or its designees and preferred investment options
to purchase an aggregate of 96,424 shares of Common Stock at the Second Closing (collectively, the &#8220;Inducement Wainwright
PIOs&#8221;). The Inducement Wainwright PIOs are exercisable on or after the six-month anniversary of the respective issue date,
will expire two years from the initial exercise date. The Company also issued to Wainwright or its designees preferred investment
options equal to 5.0% of series E, F, G, H and I preferred investment options that were exercised other than in connection with the Letter
Agreement, equal to (i) preferred investment options to purchase up to an aggregate of 5,205 shares of Common Stock with a termination
date of September 16, 2030 and at an exercise price of $1.875, (ii) preferred investment options to purchase up to an aggregate of 39,167
shares of Common Stock with a termination date of September 16, 2027 and at an exercise price of $1.875, (iii) preferred investment options
to purchase up to an aggregate of 363,572 shares of Common Stock with a termination date of September 16, 2027 and at an exercise price
of $2.1875, (iv) preferred investment options to purchase up to an aggregate of 143,724 shares of Common Stock with a termination date
of September 16, 2027 and at an exercise price of $2.625, and (v) preferred investment options to purchase up to an aggregate of 187,794
shares of Common Stock with a termination date of September 16, 2027 and at an exercise price of $2.6625 (collectively, the &#8220;Additional
Wainwright PIOs&#8221; and, together with the Inducement Wainwright PIOs, the &#8220;Wainwright PIOs&#8221; and, together with the New
PIOs, the &#8220;PIOs&#8221;), which otherwise have the same terms as the New PIOs, except that they will be exercisable immediately.
Further, pursuant to the Engagement Letter, Wainwright is entitled to compensation with respect to any financing of the Company occurring
within six months of the termination of the Engagement Letter when such financing is provided by investors whom Wainwright introduced
to the Company during the term of the Engagement Letter. Further, pursuant to the Engagement Letter, Wainwright has a right of first
refusal to act as sole book-running manager, sole underwriter or sole placement agent with respect to any public offering or private
placement of equity, equity-linked or debt securities using an underwriter or placement agent occurring during the twelve-month period
following the termination of the Engagement Letter. In addition, upon any exercise for cash of any New PIOs issued to investors
in the Inducement Transaction, the Company shall pay Wainwright, within five business days of the Company&#8217;s receipt of the exercise
price, a cash fee of seven percent of the aggregate gross exercise price paid in cash with respect thereto. Also, upon any exercise for
cash of any New PIOs issued to investors in the Inducement Transaction, the Company shall issue to Wainwright (or its designees),
within five business days of the Company&#8217;s receipt of the exercise price, preferred investment options to purchase that
number of shares of Common Stock of the Company equal to five percent of the aggregate number of such shares of Common Stock underlying
the preferred investment options that have been so exercised. The Engagement Letter also includes indemnification obligations of the
Company and other provisions customary for transactions of this nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
associated person of Wainwright participated in the Inducement Transaction and exercised Existing PIOs to purchase, on the same terms
and conditions, an aggregate of 2,306,572 shares of Common Stock for a total exercise price of $4,900,139.28 and received New PIOs to
purchase up to 2,306,572 shares of Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Terms
of the New PIOs</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following summary of certain terms and provisions of the New PIOs is not complete and is subject to, and qualified in its entirety
by, the provisions of the New PIOs, the form of which is filed as Exhibit 4.1 to this Current Report on Form 8-K and is incorporated
herein by reference. The following description of the New PIOs is qualified in its entirety by reference to such exhibit.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Duration
and Exercise Price</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New PIOs will have an exercise price equal to $4.50 per share. The New PIOs will be exercisable six months after issuance
until the two-year anniversary of the initial exercise date. The exercise price and number of New PIO Shares issuable upon exercise
of the New PIOs is subject to appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings,
pro rata distributions, reorganizations, or similar events affecting the Common Stock and the exercise price.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercisability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New PIOs will be exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed
exercise notice accompanied by payment in full for the number of shares of the Common Stock purchased upon such exercise (except in the
case of a cashless exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&#8217;s
New PIOs to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding
Common Stock immediately after exercise, except that upon prior notice from the holder to the Company, the holder may increase or decrease
the amount of ownership of outstanding stock after exercising the holder&#8217;s New PIOs up to 9.99% of the number of shares
of the Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance
with the terms of the New PIOs, provided that any increase will not be effective until 61 days following notice to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Cashless
Exercise</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If,
at the time a holder exercises its New PIOs, a registration statement registering the resale of the New PIO Shares by the
holder under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) is not then effective or available, then in lieu
of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price,
the holder may elect instead to receive upon such exercise (either in whole or in part), the net number of shares of Common Stock determined
according to a formula set forth in the New PIOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trading
Market</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no established trading market for the New PIOs, and the Company does not expect an active trading market to develop. The Company
does not intend to apply to list the New PIOs on any securities exchange or other trading market. Without a trading market, the
liquidity of the New PIOs will be extremely limited.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Rights
as a Stockholder</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise provided in the New PIOs or by virtue of the holder&#8217;s ownership of shares of the Common Stock, such holder
of New PIOs does not have the rights or privileges of a holder of the Common Stock, including any voting rights, until such holder
exercises such holder&#8217;s New PIOs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fundamental
Transactions</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a Fundamental Transaction (as defined in the New PIO) occurs, then the successor entity will succeed to, and be substituted for
the Company, and may exercise every right and power that the Company may exercise and will assume all of its obligations under the New
PIOs with the same effect as if such successor entity had been named in the New PIO itself. If holders of Common Stock
are given a choice as to the securities, cash or property to be received in a Fundamental Transaction, then the holder shall be given
the same choice as to the consideration it receives upon any exercise of the New PIO following such Fundamental Transaction. As
more fully described in the form of New PIO, in the event of certain Fundamental Transactions, the holders of the New PIOs
will be entitled to receive consideration in an amount equal to the Black Scholes value of the New PIO on the date of consummation
of the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Waivers
and Amendments</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
New PIOs may be modified or amended or the provisions of the New PIOs waived with the Company&#8217;s and the holder&#8217;s
written consent.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
forms of New PIO, Wainwright PIO and Letter Agreement are attached as Exhibits 4.1, 4.2 and 10.1, respectively. The description
of the terms of the New PIOs, Wainwright PIOs and Letter Agreement are not intended to be complete and are qualified in
its entirety by reference to such exhibits. The Letter Agreement contains customary representations, warranties and covenants by the
Company which were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties
to such agreements and may be subject to limitations agreed upon by the contracting parties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.02 Unregistered Sales of Equity Securities.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued the New PIOs and the Wainwright PIOs pursuant to the exemption from the registration requirements of the
Securities Act available under Section 4(a)(2). Neither the issuance of the New PIOs, the Wainwright PIOs, the New PIO
Shares nor the share underlying the Wainwright PIOs have been registered under the Securities Act and such securities may not
be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable
state securities laws. The description of the New PIOs and Wainwright PIOs under Item 1.01 of this Form 8-K is incorporated
by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy securities
of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 8, 2025, the Company issued 225,000 shares of Common Stock upon the exercise of a like number of Series H preferred investment
options (the &#8220;Series H Options&#8221;) by the holders of such options. The exercise price per share of the Series H options was
$2.10, generating gross proceeds to the Company, before deducting placement agent fees and expenses, of $472,500. The shares issued upon
exercise of the 225,000 Series H Options were issued pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of
1933, as amended, as transactions by an issuer not involving any public offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01. Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 15, 2025, the Company issued a press release announcing the transactions contemplated by the Letter Agreement. On September
16, 2025, the Company issued a press release announcing the First Closing of the transactions. Copies of the press releases are
attached as Exhibits 99.1 and 99.2 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<i>Exhibits</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.65in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit
    No.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Form
    of Series J Preferred Investment Option</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-2.htm">Form
    of Wainwright PIO</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex10-1.htm">Form
    of Letter Agreement</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex99-1.htm">Press
    Release of the Company, dated September 15, 2025</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">99.2</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex99-2.htm">Press Release of the Company, dated September 16, 2025</a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 4 -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>MICROBOT
    MEDICAL INC.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Harel Gadot</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harel
    Gadot</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer, President and Chairman</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
September 16, 2025</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LLoOJrhHh4o4ZQwRX6uLUtyakVbdPsm/tNsQQyAk955cISZiQ2tdIcN5WWRwxLqplEMo8IaM5orekW53CfhZ4F1bx8q4Yf2BKXkGPTOfyou/D86XtlgmEC5mMp5FMYQykTHkexH0ekrmpks0TqsKlCkhZ2pYo1PcjR+OqiVDdTcknZCtJpOAnIaj/IEolBEc6KXexA8LWZaKYDJUIDZMz8a7Vq1D05OwqrD2cXak/x18Acy5Sl4= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SERIES
J PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred Investment Option Shares:
  _____________</FONT></TD>
  <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issue Date: September ___, 2025</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial Exercise Date: March ___, 2026</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
SERIES J PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received, _____________
or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise and the conditions
hereinafter set forth, at any time on or after March ___, 2026 (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00
p.m. (New York City time) on ______<SUP>1</SUP> (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and
purchase from Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment
hereunder, the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price of one share of Common Stock
under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>.&#9;<U>Definitions</U>. In addition to the terms defined elsewhere in this Preferred Investment Option, the following terms have
the meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP>
Insert the date that is the two (2) year anniversary of the Initial Exercise Date, provided that, if such date is not a Trading Day,
the date that is the immediately following Trading Day&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Letter
Agreement</U>&rdquo; means that certain letter agreement between the initial Holder hereof and the Company, dated as of September 14,
2025, pursuant to which such initial Holder agreed to exercise one or more preferred investment options to purchase shares of Common
Stock and the Company agreed to issue to the initial Holder this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Options</U>&rdquo; means this Preferred Investment Option and other preferred investment options issued by the Company pursuant
to the Letter Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no obligation to inquire with respect
to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person so executing
such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares available hereunder
and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred Investment Option
to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number of Preferred Investment
Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment Option Shares purchasable
hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder and the Company shall
maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Preferred Investment Option, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment Option Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$4.50</B>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment
Option may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall
be entitled to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: right"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(A)</FONT></TD>
    <TD STYLE="text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
                                            to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
                                            pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
                                            hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
                                            laws) on such Trading Day, (ii) the Bid Price
                                            of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
                                            as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such
                                            Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
                                            and is delivered within two (2) hours thereafter (including until two (2) hours after the
                                            close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof
                                            or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice
                                            of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
                                            to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: right"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in; text-align: right"></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(X)</FONT></TD><TD STYLE="text-align: center; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Preferred Investment Option Shares that would be issuable upon exercise of this
                                            Preferred Investment Option in accordance with the terms of this Preferred Investment Option
                                            if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Preferred Investment Options then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Holders</FONT>
of a majority in interest of the Preferred Investment Options then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 99pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delivery
                                            of Preferred Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred
                                            Investment Option Shares purchased hereunder to be transmitted by the Transfer Agent to the
                                            Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account
                                            with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;)
                                            if the Company is then a participant in such system and either (A) there is an effective
                                            registration statement permitting the issuance of the Preferred Investment Option Shares
                                            to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred
                                            Investment Option Shares are eligible for resale by the Holder without volume or manner-of-sale
                                            limitations pursuant to Rule 144 (assuming cashless exercise of the Preferred Investment
                                            Options), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
                                            share register in the name of the Holder or its designee, for the number of Preferred Investment
                                            Option Shares to which the Holder is entitled pursuant to such exercise to the address specified
                                            by the Holder in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading
                                            Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading
                                            Days comprising the Standard Settlement Period after the delivery to the Company of the Notice
                                            of Exercise (such date, the &ldquo;<U>Preferred Investment Option Share Delivery Date</U>&rdquo;).
                                            Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
                                            to have become the holder of record of the Preferred Investment Option Shares with respect
                                            to which this Preferred Investment Option has been exercised, irrespective of the date of
                                            delivery of the Preferred Investment Option Shares, provided that payment of the aggregate
                                            Exercise Price (other than in the case of a cashless exercise) is received within the earlier
                                            of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement
                                            Period following delivery of the Notice of Exercise. If the Company fails for any reason
                                            to deliver to the Holder the Preferred Investment Option Shares subject to a Notice of Exercise
                                            by the Preferred Investment Option Share Delivery Date, the Company shall pay to the Holder,
                                            in cash, as liquidated damages and not as a penalty, for each $1,000 of Preferred Investment
                                            Option Shares subject to such exercise (based on the VWAP of the Common Stock on the date
                                            of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
                                            Day on the third Trading Day after the Preferred Investment Option Share Delivery Date) for
                                            each Trading Day after such Preferred Investment Option Share Delivery Date until such Preferred
                                            Investment Option Shares are delivered or Holder rescinds such exercise. The Company agrees
                                            to maintain a transfer agent that is a participant in the FAST program so long as this Preferred
                                            Investment Option remains outstanding and exercisable. As used herein, &ldquo;<U>Standard
                                            Settlement Period</U>&rdquo; means the standard settlement period, expressed in a number
                                            of Trading Days, on the Company&rsquo;s primary Trading Market with respect to the Common
                                            Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part,
the Company shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery
of the Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder
to purchase the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment
Option shall in all other respects be identical with this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares pursuant to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind
such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other
rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Preferred Investment Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then
the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including reasonable
and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Preferred Investment Option Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for
which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares
of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause
(A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the
amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any
issue or transfer tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which
taxes and expenses shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment
Option Shares are to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Preferred Investment Option, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder
shall not have the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment
Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Preferred Investment Option is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be [4.99%] [9.99%] of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option.
The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e),
provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and
the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Preferred
Investment Option is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Preferred
Investment Option (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make
any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than solely
for the purpose of changing the Company&rsquo;s name and/or the jurisdiction of incorporation of the Company or a holding company for
the Company), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of more than 50% of the outstanding Common Stock or more than 50% of the voting power of the common equity of the Company, (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred
Investment Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Preferred Investment Option from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall
only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the volatility for the remaining exercise period as obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the share price on the day of completion of the transaction (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other
consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option
in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise of this Preferred
Investment Option) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Preferred Investment Option immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from and after the
occurrence or consummation of such Fundamental Transaction, each and every provision of this Preferred Investment Option referring to
the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally),
and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company
prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
Preferred Investment Option with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The <FONT STYLE="background-color: white">Holder agrees to maintain any information
disclosed pursuant to this <U>Section 3(f)(ii)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Preferred Investment Option and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Preferred Investment Option at the principal office of the Company or its designated agent,
together with a written assignment of this Preferred Investment Option substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Preferred Investment Option or Preferred Investment Options
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Preferred Investment Option evidencing the portion of this Preferred Investment Option not so assigned,
and this Preferred Investment Option shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not
be required to physically surrender this Preferred Investment Option to the Company unless the Holder has assigned this Preferred Investment
Option in full, in which case, the Holder shall surrender this Preferred Investment Option to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Preferred Investment Option in full. The Preferred
Investment Option, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Preferred Investment
Option Shares without having a new Preferred Investment Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment
Options upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Preferred Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained
by the Company for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof
from time to time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of
this Preferred Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an
effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may
be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that the transfer of this Preferred Investment Option does not require registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred
Investment Option and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for
its own account and not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in
violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock
certificate relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender
and cancellation of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred
Investment Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment
Option shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Preferred Investment Option (whether brought against a party hereto or their respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Preferred Investment Option
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Preferred Investment Option, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred
Investment Option, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by
state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Preferred Investment Option or the Letter Agreement, if the Company willfully and knowingly fails to comply with any provision
of this Preferred Investment Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts
as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those
of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at ___________, Attention: <B>___________</B>, email address: ___________, or such other email
address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books
of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i)
the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior
to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred
Investment Option to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether
such liability is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option
and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder
from time to time of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>MICROBOT MEDICAL INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: top; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
                                            Medical Inc.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[
] if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula
set forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment
Option Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">_______________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: ___________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ____________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
  <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Address:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">(Please Print)</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone Number:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: _______________ __, ______</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Signature: ________________________</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Holder&rsquo;s Address: ________________________</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"></P>

<!-- Field: Page; Sequence: 18; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>ex4-2.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEITHER
THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE &ldquo;SECURITIES ACT&rdquo;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE
OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PLACEMENT
AGENT PREFERRED INVESTMENT OPTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Investment Option Shares: ______</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue
    Date: ___________ </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial
    Exercise Date: ___________ </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 3in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">THIS
PLACEMENT AGENT PREFERRED INVESTMENT OPTION (the &ldquo;<U>Preferred Investment Option</U>&rdquo;) certifies that, for value received,
_____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms and subject to the limitations on exercise
and the conditions hereinafter set forth, at any time on or after ___________ (the &ldquo;<U>Initial Exercise Date</U>&rdquo;)
and on or prior to 5:00 p.m. (New York City time) on ______ (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe
for and purchase from Microbot Medical Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject
to adjustment hereunder, the &ldquo;<U>Preferred Investment Option Shares</U>&rdquo;) of Common Stock. The purchase price of one share
of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2(b). This Preferred
Investment Option is being issued pursuant to that certain Engagement Agreement between the Company and H.C. Wainwright &amp; Co., LLC,
dated as of May 29, 2024, as amended on January 3, 2025 and February 9, 2025 (the &ldquo;<U>Engagement Agreement</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
1</U>. <U>Definitions</U>. In addition to the terms defined elsewhere in this Preferred Investment Option, the following terms have the
meanings indicated in this Section 1:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Board
of Directors</U>&rdquo; means the board of directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required
by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential employee&rdquo; or any
other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental authority so
long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York generally are
open for use by customers on such day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.01 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Preferred
Investment Options</U>&rdquo; means this Preferred Investment Option and other preferred investment options issued by the Company pursuant
to the Engagement Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such Rule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York
Stock Exchange (or any successors to any of the foregoing).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<U>Transfer
Agent</U>&rdquo; means VStock Transfer, LLC, the current transfer agent of the Company, and any successor transfer agent of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
2</U>. <U>Exercise</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Exercise of Preferred Investment Option</U>. Exercise of the purchase rights represented by this Preferred Investment Option may be
made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery
to the Company of a duly executed PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto
(the &ldquo;<U>Notice of Exercise</U>&rdquo;). Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising
the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver
the aggregate Exercise Price for the Preferred Investment Option Shares specified in the applicable Notice of Exercise by wire transfer
or cashier&rsquo;s check drawn on a United States bank unless the cashless exercise procedure specified in Section 2(c) below is specified
in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other
type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no obligation to inquire with respect
to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor the authority of the person so executing
such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this
Preferred Investment Option to the Company until the Holder has purchased all of the Preferred Investment Option Shares available hereunder
and the Preferred Investment Option has been exercised in full, in which case, the Holder shall surrender this Preferred Investment Option
to the Company for cancellation as soon as reasonably practicable of the date on which the final Notice of Exercise is delivered to the
Company. Partial exercises of this Preferred Investment Option resulting in purchases of a portion of the total number of Preferred Investment
Option Shares available hereunder shall have the effect of lowering the outstanding number of Preferred Investment Option Shares purchasable
hereunder in an amount equal to the applicable number of Preferred Investment Option Shares purchased. The Holder and the Company shall
maintain records showing the number of Preferred Investment Option Shares purchased and the date of such purchases. The Company shall
deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. <B>The Holder and any assignee,
by acceptance of this Preferred Investment Option, acknowledge and agree that, by reason of the provisions of this paragraph, following
the purchase of a portion of the Preferred Investment Option Shares hereunder, the number of Preferred Investment Option Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Exercise Price</U>. The exercise price per share of Common Stock under this Preferred Investment Option shall be <B>$____</B>, subject
to adjustment hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus
contained therein is not available for the resale of the Preferred Investment Option Shares by the Holder, then this Preferred Investment
Option may also be exercised, in whole or in part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall
be entitled to receive a number of Preferred Investment Option Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A),
where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD><TD STYLE="text-align: left; width: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">as
                                            applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable
                                            Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant
                                            to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
                                            pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading
                                            hours&rdquo; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities
                                            laws) on such Trading Day, (ii)  the Bid Price
                                            of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;)
                                            as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such
                                            Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
                                            and is delivered within two (2) hours thereafter (including until two (2) hours after the
                                            close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof
                                            or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice
                                            of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant
                                            to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading
                                            Day;</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            Exercise Price of this Preferred Investment Option, as adjusted hereunder; and</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(X)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">=</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            number of Preferred Investment Option Shares that would be issuable upon exercise of this
                                            Preferred Investment Option in accordance with the terms of this Preferred Investment Option
                                            if such exercise were by means of a cash exercise rather than a cashless exercise.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 103.5pt; text-align: justify; text-indent: -31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><U>&ldquo;Bid
Price</U>&rdquo; means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock
is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m.
(New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price
of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then
listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported,
or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good
faith by the Holders of a majority in interest of the Preferred Investment Options then outstanding and reasonably acceptable to the
Company, the fees and expenses of which shall be paid by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&ldquo;<U>VWAP</U>&rdquo;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">means, for any date, the price determined by the first
of the following clauses that applies: (a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted
average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then
listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),
(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices
for the Common Stock are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share
of Common Stock as determined by an independent appraiser selected in good faith by the <FONT STYLE="background-color: white">Holders</FONT>
of a majority in interest of the Preferred Investment Options then outstanding and reasonably acceptable to the Company, the fees and
expenses of which shall be paid by the Company<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
Preferred Investment Option Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section 3(a)(9) of the Securities Act, the Preferred Investment Option Shares shall take on the characteristics of the Preferred Investment
Options being exercised, and the holding period of the Preferred Investment Option Shares being issued may be tacked on to the holding
period of this Preferred Investment Option. The Company agrees not to take any position contrary to this Section 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 1in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Mechanics of Exercise</U>.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Delivery of Preferred Investment Option Shares Upon Exercise</U>. The Company shall cause the Preferred Investment Option Shares purchased
hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s
balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if
the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance
of the Preferred Investment Option Shares to or resale of the Preferred Investment Option Shares by the Holder or (B) the Preferred Investment
Option Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless
exercise of the Preferred Investment Options), and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s
share register in the name of the Holder or its designee, for the number of Preferred Investment Option Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earlier of
(i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Preferred Investment
Option Share Delivery Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes
to have become the holder of record of the Preferred Investment Option Shares with respect to which this Preferred Investment Option
has been exercised, irrespective of the date of delivery of the Preferred Investment Option Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Preferred Investment Option Shares subject to a Notice of Exercise by the Preferred Investment
Option Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000
of Preferred Investment Option Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice
of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third Trading Day after the Preferred Investment Option Share
Delivery Date) for each Trading Day after such Preferred Investment Option Share Delivery Date until such Preferred Investment Option
Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST
program so long as this Preferred Investment Option remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: -9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Delivery of New Preferred Investment Options Upon Exercise</U>. If this Preferred Investment Option shall have been exercised in part,
the Company shall, at the request of a Holder and upon surrender of this Preferred Investment Option certificate, at the time of delivery
of the Preferred Investment Option Shares, deliver to the Holder a new Preferred Investment Option evidencing the rights of the Holder
to purchase the unpurchased Preferred Investment Option Shares called for by this Preferred Investment Option, which new Preferred Investment
Option shall in all other respects be identical with this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.
<U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares pursuant to Section 2(d)(i) by the Preferred Investment Option Share Delivery Date, then the Holder will have the right to rescind
such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.
<U>Compensation for Buy-In on Failure to Timely Deliver Preferred Investment Option Shares Upon Exercise</U>. In addition to any other
rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Preferred Investment Option
Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Preferred Investment Option
Share Delivery Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise)
or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Preferred Investment Option Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;), then
the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including reasonable
and customary brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying
(1) the number of Preferred Investment Option Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Preferred Investment Option and equivalent number of Preferred Investment Option Shares for
which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares
of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For
example, if the Holder purchases shares of Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an
attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause
(A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company
written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the
amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s
failure to timely deliver shares of Common Stock upon exercise of the Preferred Investment Option as required pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">v.
<U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Preferred Investment Option. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such
exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such
fraction multiplied by the Exercise Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vi.
<U>Charges, Taxes and Expenses</U>. Issuance of Preferred Investment Option Shares shall be made without charge to the Holder for any
issue or transfer tax or other incidental expense in respect of the issuance of such Preferred Investment Option Shares, all of which
taxes and expenses shall be paid by the Company, and such Preferred Investment Option Shares shall be issued in the name of the Holder
or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Preferred Investment
Option Shares are to be issued in a name other than the name of the Holder, this Preferred Investment Option when surrendered for exercise
shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto,
the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees
required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Preferred Investment Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">vii.
<U>Closing of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Preferred Investment Option, pursuant to the terms hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Holder&rsquo;s Exercise Limitations</U>. The Company shall not effect any exercise of this Preferred Investment Option, and a Holder
shall not have the right to exercise any portion of this Preferred Investment Option, pursuant to Section 2 or otherwise, to the extent
that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
the Holder&rsquo;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates
(such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as
defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Preferred Investment
Option with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be
issuable upon (i) exercise of the remaining, nonexercised portion of this Preferred Investment Option beneficially owned by the Holder
or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other
securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or
exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in accordance
with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that
the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Holder
is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in
this Section 2(e) applies, the determination of whether this Preferred Investment Option is exercisable (in relation to other securities
owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s
determination of whether this Preferred Investment Option is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Preferred Investment Option is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.
In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Holder, the Company shall within one (1) Trading Day confirm orally and in writing to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Preferred Investment Option, by the Holder
or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The
&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Preferred Investment Option. The Holder,
upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that
the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after
giving effect to the issuance of shares of Common Stock upon exercise of this Preferred Investment Option held by the Holder and the
provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until
the 61<SUP>st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof)
which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor
holder of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
3</U>. <U>Certain Adjustments</U>.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Stock Dividends and Splits</U>. If the Company, at any time while this Preferred Investment Option is outstanding: (i) pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities
payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company
upon exercise of this Preferred Investment Option), (ii) subdivides outstanding shares of Common Stock into a larger number of shares,
(iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv)
issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price
shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if
any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding
immediately after such event, and the number of shares issuable upon exercise of this Preferred Investment Option shall be proportionately
adjusted such that the aggregate Exercise Price of this Preferred Investment Option shall remain unchanged. Any adjustment made pursuant
to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination
or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Subsequent Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time that this Preferred
Investment Option is outstanding the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Preferred
Investment Option (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation)
immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such
Purchase Rights (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Purchase
Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate
in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such
extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Pro Rata Distributions</U>. During such time as this Preferred Investment Option is outstanding, if the Company shall declare or make
any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return
of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way
of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Preferred Investment Option, then, in each such case, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Preferred Investment Option (without regard to any limitations on exercise hereof,
including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution,
or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation
in such Distribution (<U>provided</U>, <U>however</U>, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent)
and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto
would not result in the Holder exceeding the Beneficial Ownership Limitation).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Fundamental Transaction</U>. If, at any time while this Preferred Investment Option is outstanding, (i) the Company, directly or indirectly,
in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than solely
for the purpose of changing the Company&rsquo;s name and/or the jurisdiction of incorporation of the Company or a holding company for
the Company), (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance
or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect,
purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common
Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders
of more than 50% of the outstanding Common Stock or more than 50% of the voting power of the common equity of the Company, (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common
Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme
of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding
shares of Common Stock or more than 50% of the voting power of the common equity of the Company (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Preferred Investment Option, the Holder shall have the right to receive, for each Preferred
Investment Option Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction,
at the option of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option), the
number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and
any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction
by a holder of the number of shares of Common Stock for which this Preferred Investment Option is exercisable immediately prior to such
Fundamental Transaction (without regard to any limitation in Section 2(e) on the exercise of this Preferred Investment Option). For purposes
of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and
the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Preferred Investment Option following such Fundamental Transaction. Notwithstanding anything to
the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&rsquo;s
option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later,
the date of the public announcement of the applicable Fundamental Transaction), purchase this Preferred Investment Option from the Holder
by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of
this Preferred Investment Option on the date of the consummation of such Fundamental Transaction; provided, however, that if the Fundamental
Transaction is not within the Company&rsquo;s control, including not approved by the Company&rsquo;s Board of Directors, the Holder shall
only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion),
at the Black Scholes Value of the unexercised portion of this Preferred Investment Option, that is being offered and paid to the holders
of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock
or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration
in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or
paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of
the Successor Entity (which Successor Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.
&ldquo;<U>Black Scholes Value</U>&rdquo; means the value of this Preferred Investment Option based on the Black Scholes Option Pricing
Model obtained from the &ldquo;OV&rdquo; function on Bloomberg determined as of the day of consummation of the applicable Fundamental
Transaction for pricing purposes and reflecting (A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal
to the time between the date of the public announcement of the applicable Fundamental Transaction and the Termination Date, (B) an expected
volatility equal to the volatility for the remaining exercise period as obtained from the HVT function on Bloomberg (determined utilizing
a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable Fundamental Transaction,
(C) the underlying price per share used in such calculation shall be the share price on the day of completion of the transaction (D)
a remaining option time equal to the time between the date of the public announcement of the applicable Fundamental Transaction and the
Termination Date. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other
consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of the Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
&ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Preferred Investment Option
in accordance with the provisions of this Section 3(d) pursuant to written agreements in form and substance reasonably satisfactory to
the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of
the Holder, deliver to the Holder in exchange for this Preferred Investment Option a security of the Successor Entity evidenced by a
written instrument substantially similar in form and substance to this Preferred Investment Option which is exercisable for a corresponding
number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable
and receivable upon exercise of this Preferred Investment Option (without regard to any limitations on the exercise of this Preferred
Investment Option) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Preferred Investment Option immediately prior to the consummation of such Fundamental Transaction),
and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the
Successor Entity shall be added to the term &ldquo;Company&rdquo; under this Preferred Investment Option (so that from and after the
occurrence or consummation of such Fundamental Transaction, each and every provision of this Preferred Investment Option referring to
the &ldquo;Company&rdquo; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally),
and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company
prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this
Preferred Investment Option with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally,
had been named as the Company herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Calculations</U>. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the
case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date
shall be the sum of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Notice to Holder</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.
<U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company
shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Preferred Investment Option Shares and setting forth a brief statement of the facts requiring such adjustment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.
<U>Notice to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any
sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into
other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding
up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email to the Holder at its last email
address as it shall appear upon the Preferred Investment Option Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The <FONT STYLE="background-color: white">Holder agrees to maintain any information
disclosed pursuant to this <U>Section 3(f)(ii)</U> in confidence until such information is publicly available, and shall comply with
applicable law with respect to trading in the Company&rsquo;s securities following receipt any such information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
4</U>. <U>Transfer of Preferred Investment Option</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof,
this Preferred Investment Option and all rights hereunder (including, without limitation, any registration rights) are transferable,
in whole or in part, upon surrender of this Preferred Investment Option at the principal office of the Company or its designated agent,
together with a written assignment of this Preferred Investment Option substantially in the form attached hereto duly executed by the
Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender
and, if required, such payment, the Company shall execute and deliver a new Preferred Investment Option or Preferred Investment Options
in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment,
and shall issue to the assignor a new Preferred Investment Option evidencing the portion of this Preferred Investment Option not so assigned,
and this Preferred Investment Option shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not
be required to physically surrender this Preferred Investment Option to the Company unless the Holder has assigned this Preferred Investment
Option in full, in which case, the Holder shall surrender this Preferred Investment Option to the Company within three (3) Trading Days
of the date on which the Holder delivers an assignment form to the Company assigning this Preferred Investment Option in full. The Preferred
Investment Option, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Preferred Investment
Option Shares without having a new Preferred Investment Option issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>New Preferred Investment Options</U>. This Preferred Investment Option may be divided or combined with other Preferred Investment
Options upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations
in which new Preferred Investment Options are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with
Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Preferred
Investment Option or Preferred Investment Options in exchange for the Preferred Investment Option or Preferred Investment Options to
be divided or combined in accordance with such notice. All Preferred Investment Options issued on transfers or exchanges shall be dated
the Issue Date of this Preferred Investment Option and shall be identical with this Preferred Investment Option except as to the number
of Preferred Investment Option Shares issuable pursuant thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Preferred Investment Option Register</U>. The Company shall register this Preferred Investment Option, upon records to be maintained
by the Company for that purpose (the &ldquo;<U>Preferred Investment Option Register</U>&rdquo;), in the name of the record Holder hereof
from time to time. The Company may deem and treat the registered Holder of this Preferred Investment Option as the absolute owner hereof
for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Transfer Restrictions</U>. If, at the time of the surrender of this Preferred Investment Option in connection with any transfer of
this Preferred Investment Option, the transfer of this Preferred Investment Option shall not be either (i) registered pursuant to an
effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for
resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Preferred Investment Option, as the case may
be, provides to the Company an opinion of counsel, the form and substance of which opinion shall be reasonably satisfactory to the Company,
to the effect that the transfer of this Preferred Investment Option does not require registration under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Preferred
Investment Option and, upon any exercise hereof, will acquire the Preferred Investment Option Shares issuable upon such exercise, for
its own account and not with a view to or for distributing or reselling such Preferred Investment Option Shares or any part thereof in
violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Section
5</U>. <U>Miscellaneous</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
<U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Preferred Investment Option does not entitle the Holder to
any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i),
except as expressly set forth in Section 3. Without limiting any rights of a Holder to receive Preferred Investment Option Shares on
a &ldquo;cashless exercise&rdquo; pursuant to Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv)
herein, in no event shall the Company be required to net cash settle an exercise of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
<U>Loss, Theft, Destruction or Mutilation of Preferred Investment Option</U>. The Company covenants that upon receipt by the Company
of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Preferred Investment Option or any stock
certificate relating to the Preferred Investment Option Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Preferred Investment Option, shall not include the posting of any bond), and upon surrender
and cancellation of such Preferred Investment Option or stock certificate, if mutilated, the Company will make and deliver a new Preferred
Investment Option or stock certificate of like tenor and dated as of such cancellation, in lieu of such Preferred Investment Option or
stock certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
<U>Authorized Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company covenants that, during the period the Preferred Investment Option is outstanding, it will reserve from its authorized and unissued
Common Stock a sufficient number of shares to provide for the issuance of the Preferred Investment Option Shares upon the exercise of
any purchase rights under this Preferred Investment Option. The Company further covenants that its issuance of this Preferred Investment
Option shall constitute full authority to its officers who are charged with the duty of issuing the necessary Preferred Investment Option
Shares upon the exercise of the purchase rights under this Preferred Investment Option. The Company will take all such reasonable action
as may be necessary to assure that such Preferred Investment Option Shares may be issued as provided herein without violation of any
applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants
that all Preferred Investment Option Shares which may be issued upon the exercise of the purchase rights represented by this Preferred
Investment Option will, upon exercise of the purchase rights represented by this Preferred Investment Option and payment for such Preferred
Investment Option Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes,
liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously
with such issue).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale
of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Preferred
Investment Option, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions
as may be necessary or appropriate to protect the rights of Holder as set forth in this Preferred Investment Option against impairment.
Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Preferred Investment Option
Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action
as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Preferred Investment
Option Shares upon the exercise of this Preferred Investment Option and (iii) use commercially reasonable efforts to obtain all such
authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the
Company to perform its obligations under this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
taking any action which would result in an adjustment in the number of Preferred Investment Option Shares for which this Preferred Investment
Option is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto,
as may be necessary from any public regulatory body or bodies having jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)
<U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Preferred Investment
Option shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard
to the principles of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement
and defense of the transactions contemplated by this Preferred Investment Option (whether brought against a party hereto or their respective
affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and
federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and
federal courts sitting in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding
is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Preferred Investment Option
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall
be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party shall commence an action,
suit or proceeding to enforce any provisions of this Preferred Investment Option, the prevailing party in such action, suit or proceeding
shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or proceeding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)
<U>Restrictions</U>. The Holder acknowledges that the Preferred Investment Option Shares acquired upon the exercise of this Preferred
Investment Option, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by
state and federal securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)
<U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision
of this Preferred Investment Option, if the Company willfully and knowingly fails to comply with any provision of this Preferred Investment
Option, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient
to cover any costs and expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings,
incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies
hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)
<U>Notices</U>. Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without
limitation, any Notice of Exercise, shall be in writing and delivered personally, by e-mail, or sent by a nationally recognized overnight
courier service, addressed to the Company, at ___________, Attention: <B>___________</B>, email address: ___________, or such other email
address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications
or deliveries to be provided by the Company hereunder shall be in writing and delivered personally, by e-mail, or sent by a nationally
recognized overnight courier service addressed to each Holder at the e-mail address or address of such Holder appearing on the books
of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i)
the time of transmission, if such notice or communication is delivered via e-mail at the e-mail address set forth in this Section prior
to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time of transmission, if such notice or communication
is delivered via e-mail at the e-mail address set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New
York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized
overnight courier service, or (iv) upon actual receipt by the party to whom such notice is required to be given. To the extent that any
notice provided hereunder constitutes, or contains, material, non-public information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)
<U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Preferred
Investment Option to purchase Preferred Investment Option Shares, and no enumeration herein of the rights or privileges of the Holder,
shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether
such liability is asserted by the Company or by creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">j)
<U>Remedies</U>. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will
be entitled to specific performance of its rights under this Preferred Investment Option. The Company agrees that monetary damages would
not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Preferred Investment Option
and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">k)
<U>Successors and Assigns</U>. Subject to applicable securities laws, this Preferred Investment Option and the rights and obligations
evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors
and permitted assigns of Holder. The provisions of this Preferred Investment Option are intended to be for the benefit of any Holder
from time to time of this Preferred Investment Option and shall be enforceable by the Holder or holder of Preferred Investment Option
Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">l)
<U>Amendment</U>. This Preferred Investment Option may be modified or amended or the provisions hereof waived with the written consent
of the Company and the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">m)
<U>Severability</U>. Wherever possible, each provision of this Preferred Investment Option shall be interpreted in such manner as to
be effective and valid under applicable law, but if any provision of this Preferred Investment Option shall be prohibited by or invalid
under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder
of such provisions or the remaining provisions of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">n)
<U>Headings</U>. The headings used in this Preferred Investment Option are for the convenience of reference only and shall not, for any
purpose, be deemed a part of this Preferred Investment Option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o)
<U>Electronic Signatures</U>. Electronically scanned and transmitted signatures, including by email attachment, shall be deemed originals
for all purposes of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">********************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
Page Follows)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Preferred Investment Option to be executed by its officer thereunto duly authorized as of
the date first above indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTICE
OF EXERCISE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">To:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The undersigned hereby elects to purchase ________ Preferred Investment Option Shares of the Company pursuant to the terms of the attached
Preferred Investment Option (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all
applicable transfer taxes, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Payment shall take the form of (check applicable box):</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
in lawful money of the United States; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&nbsp;&nbsp;]
if permitted the cancellation of such number of Preferred Investment Option Shares as is necessary, in accordance with the formula set
forth in subsection 2(c), to exercise this Preferred Investment Option with respect to the maximum number of Preferred Investment Option
Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.5in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 1in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
Please issue said Preferred Investment Option Shares in the name of the undersigned or in such other name as is specified below:</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 33%"></TD><TD STYLE="text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Preferred Investment Option Shares shall be delivered to the following DWAC Account Number:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 22%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; width: 33%"></TD><TD STYLE="text-align: justify; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
     </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
<U>Accredited Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Investing Entity: ___________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Investing Entity</I>: _____________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
___________________________________________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
B</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">ASSIGNMENT
FORM</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(To
assign the foregoing Preferred Investment Option, execute this form and supply required information. Do not use this form to exercise
the Preferred Investment Option to purchase shares.)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.15in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FOR
VALUE RECEIVED, the foregoing Preferred Investment Option and all rights evidenced thereby are hereby assigned to</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 10.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"></TD>
    <TD STYLE="width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Please
    Print)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone
    Number:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email
    Address:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    _______________ __, ______</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Signature: ______________________</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder&rsquo;s
    Address: ______________________</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>












<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>ex10-1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
Medical Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 328.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
14, 2025</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holder
of Preferred Investment Options</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Inducement
    Offer to Exercise Preferred Investment Options</U></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (the &ldquo;<U>Company</U>&rdquo;) is pleased to offer to you (&ldquo;<U>Holder</U>&rdquo;, &ldquo;<U>you</U>&rdquo; or
similar terminology) the opportunity to receive new preferred investment options to purchase shares of the Company&rsquo;s common stock,
par value $0.01 per share (the &ldquo;<U>Common Stock</U>&rdquo;) in consideration for the exercise by you for cash of all of the Existing
PIOs at the current Exercise Price (as defined in the respective Existing PIOs) per share of the preferred investment options set forth
on <U>Exhibit A</U> hereto (the &ldquo;<U>First Closing Existing PIOs</U>&rdquo;) and <U>Exhibit B</U> hereto (the &ldquo;<U>Second Closing
Existing PIOs</U>&rdquo; and, collectively with the First Closing Existing PIOs, the &ldquo;<U>Existing PIOs</U>&rdquo;) held by you
as set forth on the signature page hereto. The resale of the shares of Common Stock underlying the Existing PIOs (the &ldquo;<U>Existing
PIO Shares</U>&rdquo;) has been registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1
(File Nos. 333-280113 and 333-284688) and registration statement on Form S-3 (File No. 333-285690) (the &ldquo;<U>Registration Statements</U>&rdquo;).
The Registration Statements are currently effective and, upon exercise of the Existing PIOs pursuant to this letter agreement, will be
effective for the issuance of the Existing PIO Shares. Capitalized terms not otherwise defined herein shall have the meanings set forth
in the New PIOs (as defined herein).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for the exercise in full for cash of all of the Existing PIOs held by the Holder at the current Exercise Price as set forth
on the Holder&rsquo;s signature page hereto (the &ldquo;<U>PIO Exercise</U>&rdquo;) on or before the Execution Time (as defined below),
the Company hereby offers to sell and issue you new unregistered preferred investment options (the &ldquo;<U>New PIOs</U>&rdquo;) pursuant
to Section 4(a)(2) of the Securities Act of 1933, as amended (&ldquo;<U>Securities Act</U>&rdquo;), to purchase up to a number of shares
(the &ldquo;<U>New PIO Shares</U>&rdquo;) of Common Stock equal to 100% of the number of Existing PIO Shares issued pursuant to the PIO
Exercise hereunder, which New PIOs shall have an exercise price per share equal to $4.50, subject to adjustment as provided in the New
PIOs, will be exercisable beginning six (6) months after the date of issuance and have a term of exercise of two (2) years from the initial
exercise date, provided that, if such date is not a Trading Day, the immediately following Trading Day, which New PIOs shall be substantially
in the form as set forth in <U>Exhibit A-1</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
applicable New PIO certificate(s) will be delivered at each closing, and such New PIOs, together with any underlying shares of Common
Stock issued upon exercise of the New PIOs, will, unless and until their sales are registered under the Securities Act, contain customary
restrictive legends and other language typical for an unregistered preferred investment option and unregistered shares. Notwithstanding
anything herein to the contrary, in the event that any PIO Exercise would otherwise cause the Holder to exceed the beneficial ownership
limitations (&ldquo;<U>Beneficial Ownership Limitation</U>&rdquo;) set forth in Section 2(e) of the Existing PIOs (or, if applicable
and at the Holder&rsquo;s election, 9.99%), the Company shall only issue such number of Existing PIO Shares to the Holder that would
not cause the Holder to exceed the maximum number of PIO Shares permitted thereunder, as directed by the Holder, with the balance to
be held in abeyance until notice from the Holder that the balance (or portion thereof) may be issued in compliance with such limitations,
which abeyance shall be evidenced through the Existing PIOs which shall be deemed prepaid thereafter (including the cash payment in full
of the exercise price), and exercised pursuant to a Notice of Exercise in the Existing PIOs (provided no additional exercise price shall
be due and payable). The parties hereby agree that the Beneficial Ownership Limitation for purposes of the Existing PIOs is as set forth
on the Holder&rsquo;s signature page hereto. For the avoidance of doubt, the determination of which portion of the Existing PIO is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether an Existing PIO is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties (as such terms are defined in the Existing PIOs)) and of which portion of an Existing PIO is exercisable, in each case subject
to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination
and shall have no liability for exercises of an Existing PIO that are in non-compliance with the Beneficial Ownership Limitation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expressly
subject to the paragraph immediately following this paragraph below, Holder may accept this offer by signing this letter agreement below,
with such acceptance constituting Holder&rsquo;s exercise in full of the Existing PIOs for an aggregate exercise price set forth on the
Holder&rsquo;s signature page hereto (the &ldquo;<U>PIO Exercise Price</U>&rdquo;) on or before 11:59 p.m., Eastern Time, on September
14, 2025 (the &ldquo;<U>Execution Time</U>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company agrees to the representations, warranties and covenants set forth on <U>Annex A</U> attached hereto. Holder represents and
warrants that, as of the date hereof it is, and on each date on which it exercises any New PIOs it will be, an &ldquo;accredited investor&rdquo;
as defined in Rule 501 of Regulation D promulgated under the Securities Act, and agrees that the New PIOs will contain restrictive legends
when issued, and neither the New PIOs nor the shares of Common Stock issuable upon exercise of the New PIOs will be registered under
the Securities Act, except as provided in <U>Annex A</U> attached hereto. Also, Holder represents and warrants that it is acquiring the
New PIOs as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute
or regarding the distribution of the New PIOs or the New PIO Shares (this representation is not limiting Holder&rsquo;s right to sell
the New PIO Shares pursuant to an effective registration statement under the Securities Act or otherwise in compliance with applicable
federal and state securities laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Holder understands that issuance of the New PIOs and the New PIO Shares are not, and may never be, registered under the Securities Act,
or the securities laws of any state and, accordingly, each certificate, if any, representing such securities shall bear a legend substantially
similar to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;THE
OFFER AND SALE OF THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, THIS SECURITY MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificates
evidencing the New PIO Shares shall not contain any legend (including the legend set forth above), (i) while a registration statement
covering the resale of such New PIO Shares is effective under the Securities Act, (ii) following any sale of such New PIO Shares pursuant
to Rule 144 under the Securities Act, (iii) if such New PIO Shares are eligible for sale under Rule 144 (assuming cashless exercise of
the New PIOs), without the requirement for the Company to be in compliance with the current public information required under Rule 144
as to such New PIO Shares and without volume or manner-of-sale restrictions, (iv) if such New PIO Shares may be sold under Rule 144 (assuming
cashless exercise of the New PIOs) and the Company is then in compliance with the current public information required under Rule 144
as to such New PIO Shares, or (v) if such legend is not required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;)
and the earliest of clauses (i) through (v), the &ldquo;<U>Delegend Date</U>&rdquo;)). The Company shall cause its counsel to issue a
legal opinion to the Transfer Agent promptly after the Delegend Date if required by the Company and/or the Transfer Agent to effect the
removal of the legend hereunder, or at the request of the Holder, which opinion shall be in form and substance reasonably acceptable
to the Holder. From and after the Delegend Date, such New PIO Shares shall be issued free of all legends. The Company agrees that following
the Delegend Date or at such time as such legend is no longer required under this Section, it will, no later than one (1) Trading Day
following the delivery by the Holder to the Company or the Transfer Agent of a certificate representing the New PIO Shares issued with
a restrictive legend (such first (1<SUP>st</SUP>) Trading Day, the &ldquo;<U>Legend Removal Date</U>&rdquo;), deliver or cause to be
delivered to the Holder a certificate representing such shares that is free from all restrictive and other legends or, at the request
of the Holder shall credit the account of the Holder&rsquo;s prime broker with the Depository Trust Company System as directed by the
Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the Holder&rsquo;s other available remedies, the Company shall pay to a Holder, in cash, (i) as partial liquidated damages
and not as a penalty, for each $1,000 of New PIO Shares (based on the VWAP of the Common Stock on the date such New PIO Shares are submitted
to the Transfer Agent) delivered for removal of the restrictive legend, $10 per Trading Day (increasing to $20 per Trading Day five (5)
Trading Days after such damages have begun to accrue) for each Trading Day after the Legend Removal Date until such certificate is delivered
without a legend and (ii) if the Company fails to (a) issue and deliver (or cause to be delivered) to the Holder by the Legend Removal
Date a certificate representing the New PIO Shares that is free from all restrictive and other legends and (b) if after the Legend Removal
Date the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction of a sale by
the Holder of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all
or any portion of the number of shares of Common Stock that the Holder anticipated receiving from the Company without any restrictive
legend, then, an amount equal to the excess of the Holder&rsquo;s total purchase price (including brokerage commissions and other out-of-pocket
expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other out-of-pocket expenses, if any)
over the product of (A) such number of New PIO Shares that the Company was required to deliver to the Holder by the Legend Removal Date
and for which the Holder was required to purchase shares to timely satisfy delivery requirements, multiplied by (B) the weighted average
price at which the Holder sold that number of shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this offer is accepted and the transaction documents are executed by the Execution Time, then as promptly as possible following the Execution
Time, but in any event no later than 8:00 a.m., Eastern Time, on the Trading Day following the date hereof, the Company shall issue a
press release disclosing the material terms of the transactions contemplated hereby and shall file a Current Report on Form 8-K with
the Commission disclosing all material terms of the transactions contemplated hereunder, including the filing with the Commission of
this letter agreement as an exhibit thereto within the time required by the Exchange Act. From and after the dissemination of such press
release, the Company represents to you that it shall have publicly disclosed all material, non-public information delivered to you by
the Company, or any of its respective officers, directors, employees or agents in connection with the transactions contemplated hereunder.
In addition, effective upon the dissemination of such press release, the Company acknowledges and agrees that any and all confidentiality
or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective
officers, directors, agents, employees or Affiliates on the one hand, and you and your Affiliates on the other hand, shall terminate.
The Company represents, warrants and covenants that, upon acceptance of this offer, the Existing PIO Shares shall be issued at each closing
free of any legends or restrictions on resale by Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
later than the first (1st) Trading Day following the date of the public disclosure of the transactions hereunder as to the First Closing
Existing PIOs (the &ldquo;<U>First Closing Date</U>&rdquo;) and on October 15, 2025 (or such earlier date as may be agreed among the
Company, the Holder and the Placement Agent) as to the Second Closing Existing PIOs (the &ldquo;<U>Second Closing Date</U>&rdquo;), each
closing shall occur at such location as the parties shall mutually agree. Unless otherwise directed by H.C. Wainwright &amp; Co., LLC
(the &ldquo;<U>Placement Agent</U>&rdquo;), settlement of the Existing PIO Shares shall occur via &ldquo;Delivery Versus Payment&rdquo;
(&ldquo;<U>DVP</U>&rdquo;) (i.e., on the First Closing Date and the Second Closing Date, the Company shall issue the applicable Existing
PIO Shares registered in the Holder&rsquo;s name and address provided to the Company in writing and released by the Transfer Agent directly
to the account(s) at the Placement Agent identified by the Holder; upon receipt of such Existing PIO Shares, the Placement Agent shall
promptly electronically deliver such Existing PIO Shares to the Holder, and payment therefor shall concurrently be made to the Company
by the Placement Agent (or its clearing firm) by wire transfer to the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company acknowledges and agrees that the obligations of the Holders under this letter agreement are several and not joint with the obligations
of any other holder or holders of Existing PIOs or other preferred investment options of the Company (each, an &ldquo;<U>Other Holder</U>&rdquo;)
under any other agreement related to the exercise of such preferred investment options (&ldquo;<U>Other PIO Exercise Agreement</U>&rdquo;),
and the Holder shall not be responsible in any way for the performance of the obligations of any Other Holder or under any such Other
PIO Exercise Agreement. Nothing contained in this letter agreement, and no action taken by the Holders pursuant hereto, shall be deemed
to constitute the Holder and the Other Holders as a partnership, an association, a joint venture or any other kind of entity, or create
a presumption that the Holder and the Other Holders are in any way acting in concert or as a group with respect to such obligations or
the transactions contemplated by this letter agreement and the Company acknowledges that the Holder and the Other Holders are not acting
in concert or as a group with respect to such obligations or the transactions contemplated by this letter agreement or any Other PIO
Exercise Agreement. The Company and the Holder confirm that the Holder has independently participated in the negotiation of the transactions
contemplated hereby with the advice of its own counsel and advisors. The Holder shall be entitled to independently protect and enforce
its rights, including, without limitation, the rights arising out of this letter agreement, and it shall not be necessary for any Other
Holder to be joined as an additional party in any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred
by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. The Company shall pay
all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Existing PIO Shares. This
letter agreement shall be construed and enforced in accordance with the laws of the State of New York, without regards to conflicts of
laws principles. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely
    yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Microbot
    Medical Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
Signature Page Follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and Agreed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Holder: ________________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature
of Authorized Signatory of Holder</I>: _________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
of Authorized Signatory: _______________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
of Authorized Signatory: ________________________________________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of First Closing Existing PIOs: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Second Closing Existing PIOs: __________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Aggregate
PIO Exercise Price being exercised contemporaneously with signing this letter agreement: _________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Existing
PIOs Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
PIOs: _______________ (100% of the total Existing PIOs being exercised)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
PIOs Beneficial Ownership Blocker: &#9744; 4.99% or &#9744; 9.99%</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC
Instructions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Holder
signature page to MBOT Inducement Offer]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Annex
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Representations,
Warranties and Covenants of the Company</U>. The Company hereby makes the following representations and warranties to the Holder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>SEC
    Reports</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company
    under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such
    shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits
    thereto and documents incorporated by reference therein &ldquo;<U>SEC Reports</U>&rdquo;). As of their respective dates, the SEC
    Reports complied in all material respects with the requirements of the Exchange Act and none of the SEC Reports, when filed, contained
    any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to
    make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is not currently
    an issuer identified in Rule 144(i) under the Securities Act.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Authorization;
    Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated
    by this letter agreement and otherwise to carry out its obligations hereunder. The execution and delivery of this letter agreement
    by the Company and the consummation by the Company of the transactions contemplated hereby have been duly authorized by all necessary
    action on the part of the Company and no further action is required by the Company, its board of directors or its stockholders in
    connection herewith. This letter agreement has been duly executed by the Company and, when delivered in accordance with the terms
    hereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms,
    except (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
    laws of general application affecting enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability
    of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions
    may be limited by applicable law.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>No
    Conflicts</U>. The execution, delivery and performance of this letter agreement by the Company and the consummation by the Company
    of the transactions contemplated hereby do not and will not: (i) conflict with or violate any provision of the Company&rsquo;s certificate
    or articles of incorporation, bylaws or other organizational or charter documents; or (ii) conflict with, or constitute a default
    (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any liens, claims,
    security interests, other encumbrances or defects upon any of the properties or assets of the Company in connection with, or give
    to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of,
    any material agreement, credit facility, debt or other material instrument (evidencing Company debt or otherwise) or other material
    understanding to which such Company is a party or by which any property or asset of the Company is bound or affected; or (iii) conflict
    with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
    or governmental authority to which the Company is subject (including federal and state securities laws and regulations), or by which
    any property or asset of the Company is bound or affected, except, in the case of each of clauses (ii) and (iii), such as could not
    have or reasonably be expected to result in a material adverse effect upon the business, prospects, properties, operations, condition
    (financial or otherwise) or results of operations of the Company, taken as a whole, or in its ability to perform its obligations
    under this letter agreement.</FONT></TD></TR>

</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Registration
    Obligations</U>. As soon as reasonably practicable (and in any event within 30 calendar days of the date of this letter agreement)
    (the &ldquo;<U>Filing Date</U>&rdquo;), the Company shall file a registration statement on Form S-3 (or other appropriate form if
    the Company is not then S-3 eligible) providing for the resale of the New PIO Shares by the holders of the New PIOs (the &ldquo;<U>Resale
    Registration Statement</U>&rdquo;). The Company shall use commercially reasonable efforts to cause the Resale Registration Statement
    to become effective within sixty (60) calendar days following the date hereof (or within 90 calendar days following the date hereof
    in case of &ldquo;full review&rdquo; of such registration statement by the Commission) (the &ldquo;<U>Effectiveness Date</U>&rdquo;)
    and to keep the Resale Registration Statement effective at all times until the earlier of such time that (i) no holder of the New
    PIOs owns any New PIOs or New PIO Shares or (ii) the New PIO Shares are eligible for sale under Rule 144 (assuming cashless exercise
    of the New PIOs), without the requirement for the Company to be in compliance with the current public information required under
    Rule 144 as to such New PIO Shares and without volume or manner-of-sale restrictions. In the event that the Resale Registration Statement
    is not (i) filed by the Filing Date or (ii) declared effective by the Commission by the Effectiveness Date, then, in addition to
    any other rights the holders of New Warrants may have hereunder or under applicable law, on the Filing Date or the Effectiveness
    Date (each such date being referred to herein as an &ldquo;<U>Event Date</U>&rdquo;) and on each monthly anniversary of such Event
    Date (if the Resale Registration Statement shall not have been filed or declared effective by the applicable Event Date) until the
    Resale Registration Statement is filed or declared effective, the Company shall pay to each holder of New Warrants an amount in cash,
    as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate exercise price of the
    New Warrants held by each holder of the New Warrants. If the Company fails to pay any partial liquidated damages pursuant to this
    Section in full within seven days after the date payable, the Company will pay interest thereon at a rate of 18% per annum (or such
    lesser maximum amount that is permitted to be paid by applicable law) to the holders of the New Warrants, accruing daily from the
    date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The partial liquidated
    damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the Resale Registration
    Statement being filed or declared effective, as the case may be.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">e)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Trading
    Market</U>. The transactions contemplated under this letter agreement comply with all the rules and regulations of the Nasdaq Capital
    Market.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">f)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Filings,
    Consents and Approvals</U>. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice
    to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person
    in connection with the execution, delivery and performance by the Company of this letter agreement, other than: (i) the filings required
    pursuant to this letter agreement, (ii) application(s) or notice to each applicable Trading Market for the listing of the New PIOs
    and New PIO Shares for trading thereon in the time and manner required thereby, (iii) the filing of Form D with the Commission, and
    (iv) such filings as are required to be made under applicable state securities laws,.</FONT></TD></TR>

</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">g)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Listing
    of Common Stock</U>. The Company hereby agrees to use commercially reasonable efforts to maintain the listing or quotation of the
    Common Stock on the Trading Market on which it is currently listed, and concurrently with each closing, the Company shall apply to
    list or quote all of the New PIO Shares on such Trading Market and promptly secure the listing of all of the New PIO Shares on such
    Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it
    will then include in such application all of the New PIO Shares, and will take such other action as is necessary to cause all of
    the New PIO Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will then take all action
    reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects
    with the Company&rsquo;s reporting, filing and other obligations under the bylaws or rules of the Trading Market. The Company agrees
    to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established
    clearing corporation, including, without limitation, by timely payment of fees to the Depository Trust Company or such other established
    clearing corporation in connection with such electronic transfer.</FONT></TD></TR>


<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="vertical-align: top; width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Subsequent
                                            Equity Sales</U>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-left: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
From the date hereof until ninety (90) days after the First Closing Date, neither the Company nor any Subsidiary shall (A) issue, enter
into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock Equivalents, other than
the entry into and announcement of an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent, provided that no
shares of Common Stock may be issued thereunder until after the expiration of the prohibition period in this Section (h)(i) or (B) file
any registration statement or any amendment or supplement to any existing registration statement (other than (w) the filing of prospectus
supplements and any amendments thereto with respect to any registration statements of the Company that are effective as of the date hereof
(other than the Company&rsquo;s shelf registration statement on Form S-3 (File No. 333-275634)), (x) the Resale Registration Statement
referred to herein, (y) a registration statement on Form S-8 in connection with any employee benefit plan or (z) the filing of prospectus
supplements and any amendments thereto pursuant to an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent, provided
that no shares of Common Stock may be issued thereunder until after the expiration of the prohibition period in this Section (h)(i)).
Notwithstanding the foregoing, this Section (h)(i) shall not apply in respect of an Exempt Issuance. &ldquo;<U>Exempt Issuance</U>&rdquo;
means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant to any stock
or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the
members of a committee of non-employee directors established for such purpose for services rendered to the Company, (b) securities upon
the exercise or exchange of or conversion of any securities issued hereunder, warrants to the Placement Agent and any securities upon
exercise of warrants to the Placement Agent and/or other securities exercisable or exchangeable for or convertible into shares of Common
Stock issued and outstanding on the date of this letter agreement, provided that such securities have not been amended since the date
of this letter agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price
of such securities (other than in connection with stock splits or combinations) or to extend the term of such securities, and (c) securities
issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided
that such securities are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that
require or permit the filing of any registration statement in connection therewith during the prohibition period in this Section (h)(i),
and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business synergistic with the business of the Company and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, and (d) the shares of
Common Stock issuanble upon exercise of the Second Closing Existing PIOs and the applicable New PIOs issued at the Second Closing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
From the date hereof until six (6) months following the First Closing Date, the Company shall be prohibited from effecting or entering
into an agreement to effect any issuance by the Company nor any Subsidiary of Common Stock or Common Stock Equivalents (or a combination
of units thereof) involving a Variable Rate Transaction. &ldquo;<U>Variable Rate Transaction</U>&rdquo; means a transaction in which
the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or exercisable for, or include
the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price or exchange rate or other price
that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common Stock at any time after the initial
issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that is subject to being reset at some
future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly
or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters into, or effects a transaction
under, any agreement, including, but not limited to, an equity line of credit or an &ldquo;at-the-market offering&rdquo;, whereby the
Company may issue securities at a future determined price, regardless of whether shares pursuant to such agreement have actually been
issued and regardless of whether such agreement is subsequently canceled; <U>provided</U>, <U>however</U>, that, (x) the entry into an
&ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction, provided
that no shares of Common Stock may be issued thereunder until after the expiration of the restrictive period set forth in Section (h)(i)
above and (y) following the expiration of the restrictive period set forth in Section (h)(i) above, the issuance of shares of Common
Stock in an &ldquo;at the market&rdquo; offering with the Placement Agent as sales agent shall not be deemed a Variable Rate Transaction.
The Holder shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall be in
addition to any right to collect damages.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Form
    D; Blue Sky Filings</U>. If required, the Company agrees to timely file a Form D with respect to the New PIOs and New PIO Shares
    as required under Regulation D and to provide a copy thereof, promptly upon request of any Holder. The Company shall take such action
    as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the New PIOs and New PIO
    Shares for, sale to the Holder at each closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United
    States, and shall provide evidence of such actions promptly upon request of any Holder.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces Exercise of Outstanding Preferred Investment Options for Up to $92.2 Million in Gross Proceeds</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$25.2
million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate
gross proceeds upon the exercise in full of short-term preferred investment options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BRAINTREE,
Mass., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) (&ldquo;Microbot&rdquo; or the &ldquo;Company&rdquo;),
today announced the entry into definitive agreements for the exercise of certain outstanding preferred investment options to purchase
up to an aggregate of 13,989,115 shares of common stock. The shares of common stock issuable upon exercise of the preferred investment
options are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113
and 333-284688) and registration statement on Form S-3 (File No. 333-285690).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the offering is expected to occur in two tranches. The first closing of the offering is expected to occur on or about September
16, 2025, subject to satisfaction of customary closing conditions. At the first closing, the holders will exercise certain outstanding
preferred investment options to purchase up to an aggregate of 12,064,627 shares of common stock, having exercise prices ranging from
$1.50 to $2.13 per share, issued by Microbot in June 2024, January 2025 and February 2025, and in consideration for the exercise of the
preferred investment options for cash, Microbot will issue to such holders new unregistered short-term series J preferred investment
options to purchase up to 12,064,627 shares of common stock. The second closing of the offering is expected to occur by no later than
October 15, 2025, subject to satisfaction of customary closing conditions. At the second closing, a holder will exercise certain outstanding
preferred investment options to purchase up to an aggregate of 1,924,488 shares of common stock, having an exercise price of $2.10 per
share, issued by Microbot in January 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot
will issue to such holder new unregistered short-term series J preferred investment options to purchase up to 1,924,488 shares of common
stock. The new short-term series J preferred investment options will have an exercise price of $4.50 per share, will be exercisable beginning
six months after issuance and have a term equal to two years thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company are expected to be approximately $25.2 million from the first closing of the offering and approximately
$4 million from the second closing of the offering, in each case prior to deducting placement agent fees and offering expenses. The potential
additional gross proceeds to the Company from the short-term series J preferred investment options, if fully-exercised on a cash basis,
will be approximately $63 million. No assurance can be given that any of such short-term series J preferred investment options will be
exercised. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory
activities for the Company&rsquo;s LIBERTY<SUP>&reg;</SUP> Robotic System, potential acquisitions of complementary assets or products,
expansion and development of additional applications derived from the Company&rsquo;s existing IP portfolio, and for working capital
and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 15, 2025, there were 52,794,762 shares of the Company&rsquo;s common stock outstanding immediately prior to the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new short-term series J preferred investment options described above were offered in a private placement pursuant to an applicable exemption
from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;), and, along with the shares
of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States
absent registration with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration
requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable
upon exercise of the new short-term series J preferred investment options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there
be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
Microbot Medical</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc.&nbsp;(NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced
robotic technology. Microbot&rsquo;s LIBERTY<SUP>&reg;</SUP>&nbsp;Endovascular Robotic System is the first single-use, remotely operated
robotic solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment
to innovation, Microbot is driving the future of endovascular care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Learn
more at&nbsp;<U>www.microbotmedical.com</U>&nbsp;and connect on&nbsp;<U>LinkedIn</U>&nbsp;and&nbsp;<U>X</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safe
Harbor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for&nbsp;Microbot Medical Inc.&nbsp;and its subsidiaries, along with other statements about the future expectations, beliefs,
goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited
to statements that contain words such as &ldquo;contemplates,&rdquo; &ldquo;continues,&rdquo; &ldquo;could,&rdquo; &ldquo;forecasts,&rdquo;
&ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo;
&ldquo;projects,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;expects,&rdquo; &ldquo;estimates&rdquo; and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, the completion of the offering, the satisfaction of customary closing conditions related to the offering,
the exercise of the unregistered short-term series J preferred investment options prior to their expiration, the intended use of proceeds
from the offering, the Company&rsquo;s need for and ability to obtain additional working capital to continue its transition to a commercially
focused company, market conditions, risks inherent in the commercialization of the LIBERTY<SUP>&reg;</SUP>&nbsp;Endovascular Robotic
System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways
and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel
or processes or procedures at the FDA and announcements of tariffs on imports into the&nbsp;U.S., disruptions resulting from new and
ongoing hostilities between&nbsp;Israel&nbsp;and the Palestinians,&nbsp;Iran&nbsp;and other neighboring countries, and maintenance of
intellectual property rights. Additional information on risks facing&nbsp;Microbot Medical<SUP>&reg;</SUP>&nbsp;can be found under the
heading &ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the&nbsp;Securities and Exchange Commission&nbsp;(SEC),
which are available on the SEC&rsquo;s web site at&nbsp;<U>www.sec.gov</U>.&nbsp;Microbot Medical<SUP>&reg;</SUP>&nbsp;disclaims any
intent or obligation to update these forward-looking statements, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">IR@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Media@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ex99-2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$25.2
million in first closing and $4 million in second closing, with up to an additional approximately $63 million of potential aggregate
gross proceeds upon the exercise in full of short-term preferred investment options</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HINGHAM,
Mass., September 16, 2025 (GLOBE NEWSWIRE) &mdash; Microbot Medical Inc. (Nasdaq: MBOT) (&ldquo;Microbot&rdquo; or the &ldquo;Company&rdquo;),
today announced the first closing of its previously announced exercise of certain outstanding preferred investment options to purchase
up to an aggregate of 13,989,115 shares of common stock. The shares of common stock issuable upon exercise of the preferred investment
options are registered pursuant to the post-effective amendments on Form S-3 to registration statements on Form S-1 (File Nos. 333-280113
and 333-284688) and registration statement on Form S-3 (File No. 333-285690).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
closing of the offering is expected to occur in two tranches. At the first closing, the holders exercised certain outstanding preferred
investment options to purchase up to an aggregate of 12,064,627 shares of common stock, having exercise prices ranging from $1.50 to
$2.13 per share, issued by Microbot in June 2024, January 2025 and February 2025, and in consideration for the exercise of the preferred
investment options for cash, Microbot issued to such holders new unregistered short-term series J preferred investment options to purchase
up to 12,064,627 shares of common stock. The second closing of the offering is expected to occur by no later than October 15, 2025, subject
to satisfaction of customary closing conditions. At the second closing, a holder will exercise certain outstanding preferred investment
options to purchase up to an aggregate of 1,924,488 shares of common stock, having an exercise price of $2.10 per share, issued by Microbot
in January 2025, and in consideration for the exercise of the preferred investment options for cash, Microbot will issue to such holder
new unregistered short-term series J preferred investment options to purchase up to 1,924,488 shares of common stock. The new short-term
series J preferred investment options will have an exercise price of $4.50 per share, will be exercisable beginning six months after
issuance and have a term equal to two years thereafter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.C.
Wainwright &amp; Co. acted as the exclusive placement agent for the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
gross proceeds to the Company were approximately $25.2 million from the first closing of the offering and are expected to be approximately
$4 million from the second closing of the offering, in each case prior to deducting placement agent fees and offering expenses. The potential
additional gross proceeds to the Company from the short-term series J preferred investment options, if fully-exercised on a cash basis,
will be approximately $63 million. No assurance can be given that any of such short-term series J preferred investment options will be
exercised. The Company intends to use the net proceeds from the offering for the continued development, commercialization and regulatory
activities for the Company&rsquo;s LIBERTY<SUP>&reg;</SUP> Robotic System, potential acquisitions of complementary assets or products,
expansion and development of additional applications derived from the Company&rsquo;s existing IP portfolio, and for working capital
and other general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
new short-term series J preferred investment options described above were offered in a private placement pursuant to an applicable exemption
from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;1933 Act&rdquo;), and, along with the shares
of common stock issuable upon exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States
absent registration with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) or an applicable exemption from such registration
requirements. Microbot has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable
upon exercise of the new short-term series J preferred investment options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there
be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such state or other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">About
Microbot Medical</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Microbot
Medical Inc. (NASDAQ: MBOT) is a breakthrough medical device company focused on transforming endovascular procedures through advanced
robotic technology. Microbot&rsquo;s LIBERTY<SUP>&reg;</SUP> Endovascular Robotic System is the first single-use, remotely operated robotic
solution designed for precision, efficiency and provider safety. Backed by a strong intellectual property portfolio and a commitment
to innovation, Microbot is driving the future of endovascular care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Learn
more at <U>www.microbotmedical.com</U> and connect on <U>LinkedIn</U> and <U>X</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Safe
Harbor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential
opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements
that contain words such as &ldquo;contemplates,&rdquo; &ldquo;continues,&rdquo; &ldquo;could,&rdquo; &ldquo;forecasts,&rdquo; &ldquo;intends,&rdquo;
&ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;possible,&rdquo; &ldquo;potential,&rdquo; &ldquo;predicts,&rdquo; &ldquo;projects,&rdquo;
&ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;will,&rdquo; &ldquo;believes,&rdquo; &ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo;
&ldquo;expects,&rdquo; &ldquo;estimates&rdquo; and similar expressions) should also be considered to be forward-looking statements, but
the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties,
including, without limitation, the completion of the second closing of the offering, the satisfaction of customary closing conditions
related to the second closing of the offering, the exercise of the unregistered short-term series J preferred investment options prior
to their expiration, the intended use of proceeds from the offering, the Company&rsquo;s need for and ability to obtain additional working
capital to continue its transition to a commercially focused company, market conditions, risks inherent in the commercialization of the
LIBERTY<SUP>&reg;</SUP> Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty
in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions,
particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions
resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance
of intellectual property rights. Additional information on risks facing Microbot Medical<SUP>&reg;</SUP> can be found under the heading
&ldquo;Risk Factors&rdquo; in Microbot Medical&rsquo;s periodic reports filed with the Securities and Exchange Commission (SEC), which
are available on the SEC&rsquo;s web site at <U>www.sec.gov</U>. Microbot Medical<SUP>&reg;</SUP> disclaims any intent or obligation
to update these forward-looking statements, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">IR@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Media@microbotmedical.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mbot-20250914.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamEybP9z5Z8mekhvWBxbdkKvystec0c8ijI0MSWsY4H -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:MBOT="http://microbotmedical.com/20250914" elementFormDefault="qualified" targetNamespace="http://microbotmedical.com/20250914">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://microbotmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="mbot-20250914_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="mbot-20250914_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>mbot-20250914_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>mbot-20250914_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="mbot-20250914.xsd#Cover" roleURI="http://microbotmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://microbotmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001493152-25-013743-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-25-013743-xbrl.zip
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MR\(%GD!A+42$N"'Y!@QQ&H^FEOLX#"MRV.V<J,ZJ+&9C_WBQ_7(G#(IJ^#L
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ME95LPJT;%+8I2XXALMI>[L3P6>O0(]5OS:I>)AB9ZKLO7JQ?'M:/FQ>CG"=
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M^,27V,,$J,PN(^.KE^6=F'UFLG;Q6P(Q+W)/#DE]%#?RR>E^UM(<X1I1D:5
M23HTP<X4+Q%A.WB/87WR)#:?/&R\F/;33$@3C#I+@K(X&'U$N7Y*PX*9H_F
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MA=38L8+"$W6A#*=232IJM4WW=FF;P0UW24+:5#QG(P[3RFO<Z(8#>1Q(([.
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M!"<<X'D='$6 AL<D\+5)X'<VV>7[$^33O9.#WRA1Y\/@X]&[_P902P,$%
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M=O) OW>55A<@Z+D?)+'4'&X^N7/A37/%6PXO-/B5JLHY?,"-G<RS)'CZ\,=
M2\T$-^6\A,,!\[4WKK9B[K8-Q>S,_2(J01& "_"0-EI1NE=IP%L45W2$#^)%
M&>OG\!_XC=S\VT6^GJ'H=_ZO!P^"EVF2Q<_H@#UX%YTGP8,'+YX?'OVFN\,O
M>0!&*[U(O_4!*'%5,97/M"7_(QK9SH_=L>-SXBNAQO:S:/P!/PY4D:7Q]?D
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M%(/U&CN1)\(Y?N05#I&P%D=HW09ALY:(P\NEO 85_AY'%CM'D@@+7"R:"D-
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M2Z?Z^FY8\4D?@!P^QP?/HH\"YQI*OK-XX)R,A<XIHB,LOA8G1M,<TUMJ&K>
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M;"9^6*=%7D.UCB+67.NVP690W/%"+WSW_B9[U(06O6!<J+<O3#5=Z\S+1>%
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MT@TG'2X:VM,LY.N+S)=G) *?/BXDF71<D_T;C=T]%I-YB9VUQV)9CVNSC0/
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M(HDRQ)1FYOO$YM/.,(_5U#(!,<NT]V-[G]Z^PS$92/EES;W+ILF-\*_=WP2
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MU\$J-\V@#4%"6F.)U_P8.6YGE<.FP6 !TE [H 4,IXIUF+(QNU7![L"@3,&
M]<$Z+:_K9[S4P;SUY 8DASF2HJ-JVA6/.[]&9\@G&T2TCK75B_ET[+1A'PM:
M/ 82U]%6)%T+_1ZG"U,)I8+^] >.DA'QANQE U5-9Q[Q2Q/37J?#RW9L-*+X
M;\+,V[8GS7BCQV$C%YF.SK1PY>M4/_(2X7,8+>=PDV N0WPY88G&U9RP%6X!
M>FW?W^GS?$^/;^S[CF';<]5UJU\)Z2WE/Z5VVV_F2&VATO#TA2Z\-:P>N%B.
MCMXIS7&?TI[%-&KGG/DHO7[/QH$]9[,%KFEH<X(><.TQWQLSCHZ_=+WJ^+O
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MK1<QWL(K3N/V>-QZG[R E7^%V[(DNH?7T95E< =#5/$6P@+.\H0D\#AQ7\W
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M?/UXKI3Q9C,XHF5VR-(4"(AL;B$2186SE!L39S$EMB(3-+9[/M2,P^G4S5C
M9D#U0J6167M,9CE.2'WR#<$@37?H^/+IS4';B\%F56B?$-T,31[1WJ#5"@<C
MI^@1_#E/K(_8_GC=MN&),2,(T)J4'']J1"DCL!)VQ!?F"R[#1J&OV$[@RK'@
MZ4:67&:K&1<SRXAYF4:UI ,QT^$?1+R+$0>2[7#@^SW#J$E5_2Q$"5K27PV,
MT2-23?@,A)\7\^0YSPGGC=,ZE>!XNM;.=/:3LY0RAXV@%MG/G+-EXGY+)EQG
MF6KA?%PPNQ0>!"[:ZZ(3.$'?U/@@NU6OR)7PG#$$ 6>$8I7Z9?(4NQXX 0]W
MPQ0I'$@8PQU!P M),>2I-+2<).E(V=0E>''Q:XM.1@O=!WZQ@!:'Q++42+A;
M+F7?< \TWX(M"5Y_K5.]!&9J.IJ7RD8C"F<P$^>:L+$X(8M0PAP:3!*AK2@D
MY*DDCPF9<G-%'A+*4(S=FQL'(Z98B+RR";PRLL&=LD OD(?8:CLV6PS(%^5G
M>K(-5FR#%7<E6/%-GN+KKFS4I :P*:T@D3_DQ566Q.?ZFN\(OI'LTZ7H@[6>
M^'0BB=1:+3*\[88(4>=^(&07ZR@T,AHD$_8BNJQEU OJFU+M0;TL^'9$W*P8
M!X&V#6KTN7?Z-OI6W"'G.@$I)Q6?$=9#455XBQ\79(8H49JC3+*4F<D^B\C$
M<HCOS>:UZJ1CU.4ZQ%$Y\1C13M%RD3(#42#]T?H.-Z33D*ZXRG-"=J2;R60(
MW'4*$]6Q50Q+PF!'HI9D#)GJ :QT"KGH^LP#?/?KI$+RGCU=USZLEYK%L\51
M#)Q?E!/P6O@73ILR_&(+:]5NUH]0/+#LUS7:^A0FL\1"/W$TC<XM;\3RD"FR
M'?N52UC9I) 2Q]Z,MNSS)",(2]>+:5-Y==@5HX8HB&CNR0X)U^K33MP6N@82
MB"8%BZ4@ZC]Q/4ZA5:]]EC=R)6295/TFOS@/*HCG#N^6]0AAL,IL-;9+S%;A
M.CFRQ4!?;^PQN^.W4O .#.K"+5RH"WI*A6A!$I#5;[(@T:2=Y^+"4IP71-Z$
M--&D7 9!Z>U#E^Z]"49 ?)Q/]RX5QF#'#<U%;5GJ<B)1Y&T9.U6(K*>)B#:2
M!^@9"1D:D%?"*TQOD6CFN#C/"8?LN$Y0Z*=4LXE<#Z'VB"0&HN&6'/H?^U\8
M["&Q(S;_+'B^_\+YZOD/^R]"7;2/FWOF_U3[IGB>:[62\-:Q99/J 61AD'3\
M6[H>*@S8Y^.2Q=AHE<GMN':9W:K?O,S7O5Q<KJF^7D%MN?S5HDI6MA85Z9@/
MW%5PIU9?N?IY*DI%ESY?WJ.B^&#)MV7 /)6VSDW+#-:.2<L,B6^*2\O2#6)+
M$HEF')59BH5Q$0*:#ICIT9!RH2MXFBJEM>):[1V_-ZERE@#=BGI&6N>GB1?1
M:;H$G""/YX_/GCP,9KO3W6!'>\+9-8X=Q&)]K#-1_APC*716CT-K+B4J/WE<
MY >^EH%A?REEBOW8;$!$7E_AY7@#"P[7'W^_MV0"G 9" 5A0M"%!<BVO>5MZ
MAT#[$LH2SS#/A!R0][NGN^TB#3;JLC/"%>?2RX'P S%S7RW#E9U_5(JOF'HS
MGZJ@5FB)-BX8A1Z"C<-C")67WWG8>CX!UONK=- :_;<831(=+D38RX-63C,,
MX^DY<NIQX!]N=<#6"JLJG8+&J,'0P21%"B!GC,9'B6!\WH$^7UQP('1K)PG6
M6L U?HGXDO]\\/^VJL_7]4\^W?HGM_[)K7_R+AWKZZM0+,00QIS B_-UZA7&
M.BZ<@MP:,241?2*SM?!@!$/0A7-I:@SZYK7K]UF?#(7189WTU)62 8E/\ODT
MD;B8KITX\1"^Z,!)+^$2.T\,!$:\'?K&.R=BTY1KM^+8,CTK_@^:U59F96IG
MQ*]M6:XCQ$$/#6%1,/()UZM]::H$7-"T(0HJ<3Z&N4D1?%)K<GN]WH%!_:4#
M!^P7:O)@HJLN%DI94B)1DTN\PJC:G9J9DG&:>H#C[JY[#/5>PCN@KY:]?NS9
MI]B_VZ[4Y1K7LP&L9^N34E==F ,<D(0+,XO_D="GI <324(,N@KJ].C\3'+%
M!WLBJBORKGC.//82,J437LUPBA"E8O(#-\,+,"A#H"ZVJBEYG0U=IP7^D/TA
MV#3QKHH<)&]#VURRWL\N04*54!E2PM\Z@]^>XCLPJ ]"/X+<&TH5);NW]ZB@
MEVI4F5Q>43+LEG3@W&B$)+$P_7Y/(YC,WI5R>;E$7\A!D^3)))4T6-IM(ZY^
M;B.,RA^*A?)PE;)&V7O=+?L[/D"M/V39QG)ALU-)V?J($LUC8U3K>]@;U4)>
MTE)F8/-J'X(ZHA5KU(:QUWF'-)SM:;X#@\J$E@63_7 --RNB-"UB1AOB/37E
MC:HU1;O7!:THJ8O&BZ)K'@E0LNY$K87M[_1NNJ>;9RI707)9*S/\.RXYQD!G
MH+BD5".5=!1K8G4OUS!RH/).T2C!74:FV))UC^/&H:R$9OT%TA Q[)I._-#R
M9AV"GUVDHU343@J0T@O[O?8W:H2QO,L9F.VUG^JKXP[Z31(RD/=0NH7.79#/
M(I-V66*DB$GNG&;,S5,Z#Q$X=*-;:7L.;]\YS/D<ODHH6N 85A?R"29MQMV2
M>TNK9!BP/!M#]"O^1R[@#9-;'FI3I=^30&/HQ+ B@W'9[JY;/H:6W57P[AHB
M7J0L<K#L3JFN^5RSMP7V*T[H&*-LCJ68%87K2"M6YF>NE8Y!7@G)8>URA@S5
MHZ %F !I'F6*"U@1/$<'M/6V^IV+8WR9J@JW7['TN\VN[NOL]?]I^>^NC>'Y
MD9G\HQ=WL/,[YB3V>Q2&>$E!8C6@\>R;,,DX2Z+R63 JJHOO;GB<=_1\V&YW
MB2;^N(TF;J.)=R":>)^.YLW2GAX=]WN_'YT=#T]/@]]?#4^&;U_ZF. +L#3'
M$>G1:Y5H]M5)K>*8/?.&B9,3%.<Y/%0C%F0>;X9Q$;YGDI:8H$UL-NBT1/:E
M>*O?=)/?UR4]NG?/._C8@TT%"XJ#YR@IKLG^@*:DR>#@+0[[^._?/?X,\^;Y
M_HLW1P<G;_??G@5OAH='!WNO@Z/C@UU$LKHO)4GW&1.@?R43^B/.YPW,2>TM
M7^(E3Z_Y+9\[TS<PXD]O<G_Q;,4,KE6DMK/:VN1Q-$W:YG4[84N:/$-8P)>:
M,5$'MQ?YIQEB/VT-L:TA]LT98G?590CZX_';LZ.#8;_W]F4P_&-X<G!T.O2T
MQ[MMTVQT4#8=&I_(A^:?GG3S]OHF)\G,#7;_<.7/Y!TMD0@YCM<TN](VTP87
M)0QQ/ILE)58&@]NY\*[F)2+@VE=\99_0+DK'90$KPH*DZW]O$C3JL^ H'S>,
M*%(.K)SZ(E?M'3UV=]#?M/-HT.]AB)8  Q@9LRBV!,-IR@.&ZYS03M4Z:]5'
MG0RE&JUU(C$W!*:OY ZD@&\Z<<IPI3DQ$4MM/<*H23XOX7MT"0YYC<'M,FQ<
M?AQ"E\Z9E)!S_1&9ZT G#&\X%\P0S,97J9I^S:M_?[;QXP%&GGBQI0HK,F(+
MU_>44E-A@V'I)KNPH^+CX-D]&/U-<B9W#O=?[Y#^T>_]D\I&1E=P1 FU;G)!
MWN>$>"(:5?5+4)3W:N3W=C$G#C"9*P^T%#W=B.8Z4I0!K?FBPV4LO"@!YEG4
M[WEYU6H^4DYYZ'!%OE1+%ZAQ7=M(KK1I]#&=SJ=K!E$GPI?+E212_9)L4$(Q
MKTJ,P/)5@[ESE]-]NHN>X%V4<:4&JI6@L$I"A_VLJ=ZCJ2%;=M4R)L!QF#CH
M03X$DNV"4;XD*ZZ^SJUVW8BO_UG]W[T8XY?U97[KW3[#RAL=3J*#^].D'2*1
M+?W%X>][!\$>7#=8V>681/Z7.79W=!VWTF*[7-OENJM#N0W+=4^6YIK5S:>2
M.C=F4@)SK:%=K!,P7#62:Q!\G\7(Y1C97Z7RJ^]+^@85RSB9$&$]J)TGIH!P
M<(A&"!A4YU3202>DP\5Z:C-K][CBZZ.?GSRA<EB2E7?70&,KW>UW4@=:.:)_
MG![]>KQW]OZ$(V.OWKX^')[\\VL<DCN2-7OC8@I1,Y0^QV<:]<XA$D8L/(K&
MS_KOSLW)\Z,73KX!S,V>A:[R%P63;=3G#+,1/F'>[MP$F4W3-C'7LG'NW)00
MF.IFY^3N3<HA7.#/^KWK&/N]F(_;ARO[OUM<V197ML65W<A))#:?:X:5#?]X
M=;1_=-;O[7])--E6P-X@7% ^N$IPNSP+<J02R[Y[L7>*MM*;X3$L]LNW)V_N
MY*!4M<@2/2;Y[#(JTRBO:I_6AW\3*]G-+GQ\S88AIB^?%5A& _TC.E[,U>%7
MU_>0Q#J.%1/*A L$SF9$=BTLU XO]&YP6'#%'^7^RHD[<]+=FIP^@\92S&\U
MN/FL\26>++#29]<K0F\N$?[K["X0#?W>;WNOWP^#D^'!\.BWX6'8?8^9,@C"
M/&>)YBK-DE@FAC!1B8.O*N['9OB*+EH]EKN?Q*E_I1/_?OZ<Q+]E.5RUESR^
MT13&U8:.F;G/&^D]SRV[@29W!/+RKDSS:O#MS5RW[7E/MN2>U G:;LI;,<PO
MTN37FK$6S>#=19$G#<S-]GAOM^BMV:)#XI+[LG)RNT?O0).W:(]B_"=NQ+X"
M+/E7B^!L9_=V#.]>S5BM.K")Z2^/QFYG]Y8-[U[-6&T_[K740KTGN_'&<[F_
M)=_@JOC]?_XBGES81J\C56W#^;<]:/V5=NX/^V\/_Z2C^>KLS>L7_Q]02P,$
M%     @ ?(@P6RVR>BC$4@  _3$"  D   !E>#0M,BYH=&WM??ESVU:6[N^L
MXO^ E^I.B:]@Q5LR'<?M*BUTK'FV[)'DI%-=4UT@ 4J(08"-"TIF__7O;'<#
M0!*T)5N2F:EIVR2(N]^S?><[SU^=O7G]HM][_FJX=PA_!OC?\[.CL]?#%\]_
MX#_AVQ_DZ^?[;P__"$[/_G@]_/MWDR*OG@6/'LZJX"R=)BHX3JZ"DV(:Y2%_
M$ :G29E.OH,?PD_?;?J[7X)I5)ZG^;, 'S7__]V+YR_?'I^Y;WLPB:9IMGBV
M[GWTK$K_DW#SW[WX/A^IV2_/?\ 7PGC?76]/?PFJY&/U(,K2<_BJ3,\OJNOL
M_//]%\./%^DHK?J]I[N/G_^P_^++C.3/N:K2R>*N+L0-=/]X>'3V:GC2[YV]
M.CH-3H<'[T^.SOX(CM^>!/"Y_N!H>!J\A(]^?W5T\"KP'X6_#_\Q/#DX.MW;
M?ST,7NW]-@SVA\/CX&3XZ]'IV?!D>!C\#HW4W[=W? @_/'BU=_SK,#AX^^;-
MT>GIT=OC?J_9M/TV>/L2?H@'>>]L&!QA(Z^/]HX/AL'[=_#MWC'VY<V[,WST
MY<G;-]*)DSWZY/WQX;#Q\KV#,WSKHY^?/ F#/?CWFR$\=MCO[>"#WV?QO^?%
M+_[SWY?TX2#$0<#_'!R\/3D\.O[U]1]A\&8/9^\,I@#>^I)&#P,Z??N:1CM\
M=Q:\>W]R^GX/UN_L+748GCHX.X)9\_I*(X2NG/5[R[M]4G_9WF][1Z]I'?QY
M"/%9F*Z] -Y_? H_QF^PGZ?O]_\;VH??A]2$UXF3X?^\/SJA;IS"PKQLZP2N
M([Z9)H&6@E9[[]V[UT<'U!5>+.=GK_=^/]VM;2-\3>WML.3OZ06TMK+)AM(/
M][<XYS#?[UX/#W\=4F\.WAX?#WF0W)M@_^WQ7O#RZ' (3Y_\*AU^?TR3^!:/
M0/#Z+4P@O1/>L0][[#WL==N=W6L[XP^J8D;GW'PP*JJJF,IG[HD?)WF5E'?U
MOKK^WH/D>/=Z[T .QMZO\$?P[F0(Y^R$%OZWX>D9?A>\I;W_Y23+C0Q5K]5=
M'82\O2JC7$V*$C;X?#9+RG&D$AK?FW1<%K#W^[TW29R.HRPXRL>[]W>\R]?S
MC.ZY@^'KUZ?O]@Y E/S]NX??T;_?[1T>ZG]O/ =7:5Q=X*,/__I+,"K*."D?
MC(LLBV8*NJS_]AVIS\_/3C9OX#(I*UPX/:-PLWTGROCSL\-/[O!/#_]ZG4?I
M79E,DK),8N[947Z9J&H*BQ^\G55ID0>G%U&9J&?!O^@_LSAGA]<PEJ?7.Y8C
MI>8)]^HPJN#CYR<O_F7_>_[#R0NW__ _)[=E>6]0C'W.2EWKZN1IE489]V7X
M$<Y^JI(-%^H'N@Q>7-^M]R3-Y69*\SC!-SW<_3'-[XQ6<=?[WV[%U8;TZ'H'
MA IROV=TI6"MJA3L5!>)-G>>O[=W9O.Z?/[#^Q?:! (9"E?$)(7.51=1%4)/
MRN RRN9)4";C)+U,XK#?^Y?[7P!/I)4*(J5@/E2]X5=%!F+*:R-5 ;2>5AF\
M#$0J7-CX$Q#=4WA+'@=J/OHS&5=P/=$763I-JPA[J@)X-I%CV._AL_C N,CC
ME+^_2,HDS:,)O"Q0287=KR["(*K@Q8N@@DG&5T"/^9'F&:YW7VX __"[H^%N
M\$MG90K_"]W^\=G#A\%L=[H;[. :_U&4'X*#M.(>#/!IF;M::V<P!]!]$F+U
MAH+1O KRHL(AEPGU/\2V8+;4N$Q',"&X6-B;V;P<7X"6$DS*8AIHM2QPM3*8
MD^ PR:(KD)0P@>6L*+G96H\.BND,IL[M"*X9-BQ#4"1L@YU(Z87K]^#;*,:#
M0=L,^SN'<X'][;HI189[$U!, NC.%+^LBO$',#GA;6:L,/GC!)\I\H0[U>_5
M?A%0+Z 3L -7M0V_SK)@E 3)O^<P7[(/S19XARW!!*H@3B9I#J](H0$8./[V
M\<YH@#USF^CWFFW ]R/8JN?P%]  :,W4/,IEU\.&Q9,8P8N'^7ETGM!/]\[+
MA/\V2JJK).&#(TM$*_]J]V W^!U^=D5>ON#[:#K[!9Z ]7[]^@".;@R[*L:N
MP]2\B1;!XY_#X/'#QT]I.!&\.TYH-_]WE,^C<A$\H:]_I)>_3$8E??BS?%C;
M*VT]=1?P^DSNKW\ARU"TH/EJ ](M_Y\'#X*7:9+%SX)WL B_P.O_/4_R,78X
M>/! JU.'1[_I+M9\%3^AO2,VA?YL/XO@T#R"'JDB2V-HSAHVKB%3-W2DA:46
M2LV2:4ZN56Y;5%9_<K)D0K\P>F+3(O2:L\J!UM*TAO;\!YB=EHD:P6W[X<$H
M@=L5>CBCV74]/S]QE[^5F7%VV@^XU7AWW:'3?!O4PVO7>.'Z%0G4[SW"2W<W
M@(\.43ZQ:L2?'>4@F%E9TF*-]2XMR9),)5<HL%&FK1.4+,\GL'>+*Q1E_*J+
MZ#+!+_J]:1+E\+F"=Z'F4;&DI+=J<?GHV;U:AGNXLZQ\WYM,TBSUU5)>9$7J
M];ND5*3,H^$0IV P5-F"S(/<_*NZ*(OY^04I:?#-M*"=AAL'E-.H3+$GH,]7
M99$I^JG2_P1K(1@MY#-6Y,:LV\D#_=Y56EV 7LO]((U&S<<7VK* EN:*MR!J
M,_ K596H>O'+3N99$CQ]^*-1$A/<I/,2#@O,U]ZX^JKJRW:G;K)3]XNHC$G]
M/Z2-5Y2N)1'PEL45'N&#J O'^CG\AZ-5;Q?]M@_)+OI<@0A3JM\[C!;-Y<8;
M*@:+IT#[&2\IL-FB:E["9_!V./0172[\-?TC#ZXN4K@_\)I!TP],P5&4?T!Q
M1J8G6?2P78R)CU=,-*\NBA(ZB/NO#$I0P].2KRZPME'HELD4[;IQ5L!M] O8
MK<5E&J,KY**X2B[12D8[?IS!;3A!J4F"MM$'ME'1'P!V:HS&5HPO'[D]")P.
M]'M+>A#$\P0_E(E4%0P=S,^+8IK(!(;FNXLD@\L4%O/!#$R#QO=YD3^ !4#G
M#O0SF<ZR8I'HI\CKDB]@5FB&50KK'<%\HR:LN*=P'Z=C<?3P#8Q=G)=DUN/Z
MS2X6BEP8HS+*866R8BR.H8C\(G*,4;&07YP7,*,YZBSP*YD96#55]'M9 2I+
MQ/= DL'/RB)/Q\$$M@)\2$$?[.="50F(CYTT'V?S&-4<7)XK:,@\I,@WT7F;
MG"=Y4L+J+0)V4LS D,=W@G3";3*&@P.37Y*WBP08[,:O>P]M;Z'.MQ#ZFU*E
M?+^JUI)PJ[T'A1Q.W6D%BI1R50Q42H8?QW QG9/XD==L)=!M'Y*W]FB D;.Q
M7>$0E561.])7-<)@%FEG^U\>[CY\%,SP_D%/9DB; ^\SOCQ!."C25)3=/J!%
M%R*P\-+H]YSOIG"G&Z\QR@BX)?$5Z.DG*<&[+M[>,G=QIP5#$/&P;Z#1%C47
M=XVS%?P]I^7LZ7RD4C' 9!-=%?,LUH$:>NB"0CD<?\#7%$$T)N6BWW,#+*['
M/0R,V P#-,^*>>4$=$+6RI(1&(PSXV=0_$OR8(=!(:Z&JZ@LT3]N=+24[#=R
M1Y##/%5^/\# (Q_9*$OX<, O)7@4X6?T3][X]&\0P:%Y^Q4Z^F7P:LGH)2(6
M^E&)^[7C[O,ATL*VWP/KOOVZ=L2S$<WP,)ZB1S\_\:(F?$?CC\IY)N*\3,[G
MF6BHH.=/Y]DY><$J$Q+;;I?;/B0;K22W4JOOBSQ<8,5AM!"EJ8VGDE"O0-]7
M%^DL!(L!>DV7HCS"XG>>>Y^ 9"[ CN#?_UG Y15<PNCFJ C0Y0G/9&DT2C,P
M+?J]L=8?^%'6+<R'U@(*=L@$"R(P0,9T]:OY"/NM4H[!X\4VL!<L77\+;4E]
M@#%N=^MM'U(SMMX2?&YUAJV)B1/*@;:%%=2I?8JEM-+1[-'"TS)T<)N0 11+
M;PD5;S?7;1^2V5SH*^_W'CU]VMQ(Y$:';SQY9[>#&+4UN$/=U6Y]]_0Z-%_0
ML:7A"26'#& C5KB_">5"*A^^#/X,Q==DG$PHD=G%I.6Q8PY%,6S>UDY>1)?H
M[T&$31614ROC9Q1T!8<P*T!+Q).13"8$?'&[O=W/MWU(9C_;W==-%[0JX).M
M"O@M[1-M)B^6A$"5>:!N:!.P$7WV8,E2?#V:S;)TC)8G;)M,%6(I)VP2DQ_;
MC9VN>#7F)DBX00SR6/"-Y!*'[1:P;O<-[+354*C'6RC4%@IU9Z%0,HKM5=WE
MJCXK(_0Z+@L&^Q%>K?<9H'!*$4#!PD:!O"QX$Y4?DJVA<NN'U-P%O'+MWG$1
MIQ;'-J6'E>LA5JLW2Y8J<>7 N_%O&,^M9-=(@@,*XGXOS>$1L)I!(7Q&'Q__
M<3H,]J8PE'$DB+KC2,71OX.#:)9BV)K[[GWU:U:,5GYS2A%M>4![^74$VL0-
MM$MS1]M+\_$X40IA,.C==^<&]-@"!O-U0=S;S;_AYB=X M@TYSX47S;_;[P-
M]'.<(\!ARGE94F!%PR#09U@U I8Z*FGVS>H?;/?.+1^2BR)^;%#$.O&%/KA7
MX[W9)<3>?I5A10,8A5TW/(5K\O]V _?ARLVKHC"L"LID5B8([=*>LC7^8O;9
M@6T,6A0&/$!X%NR$@[]C3*26E5?2G\I+S\-^M";@!3;GCHT1>K2>/8?]C),L
M!?-@83S/)O ]025PGBTP)CR>X[#>';X$ZV-&5OPTK62DR8-IE&8D(N6O455%
MXPL<[$#/UG%12?:9Z6>::\DYA>[FT$I,9GA5]'NUQ*GFK[VTJ>#W%*:;7Y=$
M99;"U,"S.^F 8-0[CP9&03V,V-.PD\*7^'P^GX[X<><11=&A,E6D&I%OJX)?
M(13V-*FJC!WS[V!W%3$E]K7FN<4#[ %G7 [<+ #M=(!&=;(F.<EPH524QBQB
M.#%4<(RR3-R9Z/P<M U\@Y]RQTK51;)RWW'>8*!FR9C1+3)QUMW2MEBPSAZB
MCYPIXTA=P%Q_7RH"/P;CBP2D95Q&5SF;!3Z4"T%_P3S/0!"R#(6?TS_,),S*
M8IS$B&?TNF>G=#R _0S3B"JE>81TQK5#V(7/X&4?'A1P8.$49&W#-(F-&A4:
M!GFAUP!/Q32)X:_8F?-YA'"+A)5#BOS ZBQF]$+[)7R7%U54IO^A<S?0T<*V
M.;;-<NJF/HK</*6-Y$50C."NC'2&2IK3+P@[@@C1F<XO]8 :XR*?I'#.:);F
M\+\YM"ZQ2_+7P^V+6-]D1PTH72"B[4QAK=:^YK+3+&)47XN<XZ *N3;H!)'+
MOWU)*NPX1@_H[$%K>)+/Y=3HX <E,$3EHN5@",#7P(CA%QH$F^%%A6J:SFGM
M]U8=C-K]-X<IRMSVX+(WESYH=="V#+G#:8LNX5ZDC6F\VC8]>]7OL=$1)K+J
M,T('8C)'-VEJ\-?0HY:I\0>_JIG&Y4\ ZR@?)YE$@S!N4_"?91+!"L-@%G!>
MHW$E)TXF@R\VUQ2<+#MLJ=+7&J\;I41I33AX!R*04-+RN""SUDA5F.QY5E':
M<&Y62[$PFQ6E1CY37E>!MJ.]_]M>V^^M74?W=)( HD@7OA#N*9 0<N$7\\KL
M\M5MUK:.# (;[?=LJY2D$T33 O:IGX;MW(*?TI"^?&0KZ4WJW46HM:1T22#&
MJRACA-M;X?9IS9JFM&RD6\.L8<N5V._)_F%+G'+KY20ON;:N6%'06H'.B""U
M )XCP-JL,HWG] ;0\?=?U*:$(A9$Z) D(:4.1&#AS2H\,UTV*BAWXP]Y<94E
M\3EK:Q&&^24W#%['I\S<JI@#H1CX+R\'%1%^$LTN0JM:L'I@--.V7=]A16IT
M!!NMICD@3+9@NF(WKBBUY[!N.:NV$KT6O2 26<X[6U4, 1)=,1H[H9J;H\WZ
M:H;)*M*LU9&;)]O(S39RLXW<=#A'=_^6&-7<%V3\L9<"Q91C3J'\,TD2=7Z8
MC=E>8%;_PCQ ^R_"M60V#?:31G=OG/?DJZW0/?6;C7GC'6C#W7-\!D<3G67(
M'BO'NZ%S I@X0:$9RWHR: &( $I5)?1*)/!I(_''I$&'.D #>A!9N'.%J%YM
MIE9B+=*+*T=)U_X0=*M8$Z6#&B-0-U;X2 U:0?9@C 149 BI,K*',%[NV^/<
M>YRJT4("#J2QR9%IN$=T;")UK2O7X@,]U.1DQ$X"!KQS(R7.,R<P7I=2J&(D
MTXU>0P1SH[K_SYV]!_N#8.<?@__%SW?V!J -$W[GQG@K;MFAWD@EV'3H0IW<
M($XF/<Z3ZIOH#(97O<$AJ5]YG>PQQ%79;./A[N/&0EZW&@#;T>.<;->2L%4S
MFP]W'WW.MOGNQ=\[M'@#Q/:1DIH0'?^S7H)GY"C'H_[;[WOOM*GE.LS3*9&/
M5 FY?.!.B>MN;-_OL%E/VCQ#8G^W.XW0<H>#<&$#$V@_6U>2!=-OT@VX[JR?
M.1IHD45^;,3"2 H=2QAO>N!:WWF\LDN;]<2%?B_MDML!0ZM(CJ99DA.H8J(%
M"2-L#=QBL\Y<%- ;+7EJH0["GO_T\.'.B-S:)Q8\?OSFU /S6LJ821)C;K^3
M<;E9?[+H2@U,XK\S"R''=*B1_31F+7.S=]M@O-61Y3C %.?C= 8=]Z%.[!!%
M'PL+QOVL*%#2G@>O=]_M!CL.^X;^QB?'W*1_D<E.U0J6U0!,$$;<[M;CLSJP
M(T?M\X^LLGL_GI/;LWW[^3NJOI<WG! X9)X76?Q[U55!1Y*:8O60 Z8.287X
M][TG351ULVX03\CR [=ZQ(-UYWW#/8R#3%LN]/:K>LF6:+AA^;&-CY.[/:)&
M$';%'?_%[G<;2-]T%=T+:+.NP/CKZA&S87^>$G=C&MNUJ6AM+7WE=CY7%6MM
MZMM8S3:%>[^KPGWW-.R-Q4(-G-$M*J3$ER9@&%*<?L$+<'MA;"^,.[Z:;1?&
M/[87AOEO(R<=V:/,03-***V<]#DJ%Y!X6,5T0Q-K5>,(.QACQ)\"W00ZJ@Q'
M;H<;;K.>:#^ &<\5^H]];RFZ2>T#9509]L*HB3#;;;E%;0&2ZW-2/GKX9/?'
M>G&S=C?E@R>/\-';RM;\22/I0+K^=!NOWL:K[TZ\^@L>Z&\EG @'&P[R>5F
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MC$%&$#Y"<OMX*@UG)MUTI'#J K.X^+5%)^.%Y('/YM_BF%B6DPBRY5+V#?=
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MIUOKW77V3J8IGC.9LS=:&8./52Q$8AXK" #H"@>/%\G8Q-/U5]WU=BN;G<_
MG7\<SA]GS9Z^9(WW1L0*#\. B$VD';'2G37/&4\220@ I'A1:'4E,VY%.F5/
M-S?J60".0EEL1]*PX5"+(0:U6T,'C2)  Y-BK!T))BH$DGAEFM($9J2T[4 A
M&3ZH@"AG0%0>B ]W/*D8?%.7^9#^_H_26#F8?DOQWYZ\?_-V_UT$%\.-Z=+
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M;>9]\('=H1J[_.UN30 &<<IE9EA]L<"Z"GL_K6D373,H$N)5/NK<%JO$52S
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M93E/GN0F16,ZR@T09J*61D;&D"R$#@"SW$H>CLU5$&R2ZCDZSJH47GA0],Y
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ME+L"P&I+=WVC,(A.MSEJ??D;?>UIR+_<18_2% %>2+#+7 _]-I/F\%_7!(%
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M^*8(4!P:']0W"H$Q5(3IO'.@Z\8><&^K+;YQO]P;6>V1_P%02P$"% ,4
M" !\B#!;&Y=(&OLO   *  $ "@              @ $     97@Q,"TQ+FAT
M;5!+ 0(4 Q0    ( 'R(,%MBTQWN+E,  %0C @ )              "  2,P
M  !E>#0M,2YH=&U02P$"% ,4    " !\B#!;+;)Z*,12  #],0( "0
M        @ %X@P  97@T+3(N:'1M4$L! A0#%     @ ?(@P6XV@4RUW#@
MOT$   H              ( !8]8  &5X.3DM,2YH=&U02P$"% ,4    " !\
MB#!;0-U*C" .  #(/@  "@              @ $"Y0  97@Y.2TR+FAT;5!+
M 0(4 Q0    ( 'R(,%M"$YU6*"8  *L# 0 +              "  4KS  !F
M;W)M."UK+FAT;5!+ 0(4 Q0    ( 'R(,%O^+)!I*P,  /<+   1
M      "  9L9 0!M8F]T+3(P,C4P.3$T+GAS9%!+ 0(4 Q0    ( 'R(,%M\
MHT[ _0H  '^&   5              "  ?4< 0!M8F]T+3(P,C4P.3$T7VQA
M8BYX;6Q02P$"% ,4    " !\B#!;I!<F&EX'  #B5P  %0
M@ $E* $ ;6)O="TR,#(U,#DQ-%]P<F4N>&UL4$L%!@     )  D % (  +8O
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mbot-20250914.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000883975</identifier>
        </entity>
        <period>
            <startDate>2025-09-14</startDate>
            <endDate>2025-09-14</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-14" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-14" id="Fact000004">0000883975</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-14" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-14" id="Fact000010">2025-09-14</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-14" id="Fact000011">MICROBOT MEDICAL INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-14" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-09-14" id="Fact000013">000-19871</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-14" id="Fact000014">94-3078125</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-14" id="Fact000015">175 Derby St.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-09-14" id="Fact000016">Bld. 27</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-14" id="Fact000017">Hingham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-14" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-14" id="Fact000019">02043</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-14" id="Fact000020">(781)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-14" id="Fact000021">875-3605</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-14" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-14" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-14" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-14" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-14" id="Fact000026">Common     Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-14" id="Fact000027">MBOT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-14" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-14" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 14, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 14,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MICROBOT
MEDICAL INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000883975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3078125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">175
Derby St.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bld. 27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hingham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02043<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(781)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MBOT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://microbotmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="form8-k.htm">form8-k.htm</File>
    <File>mbot-20250914.xsd</File>
    <File>mbot-20250914_lab.xml</File>
    <File>mbot-20250914_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>25
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form8-k.htm": {
   "nsprefix": "MBOT",
   "nsuri": "http://microbotmedical.com/20250914",
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "schema": {
     "local": [
      "mbot-20250914.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "mbot-20250914_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mbot-20250914_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://microbotmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-14",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form8-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://microbotmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
